KASBP
Korean American Society in Biotech and Pharmaceuticals

2023 KASBP SPRING SYMPOSIUM

EXPANSION OF DRUG RESEARCH & DEVELOPMENT IN COMBINATION WITH **DIAGNOSTICS AND DEVICES**

FRIDAY, JUNE 2 – SATURDAY, JUNE 3

The Westin Waltham Boston | 70 Third Ave, Waltham, MA 02451

SPECIAL PANEL DISCUSSION: RESEARCH & DEVELOPMENT IN COMBINATION WITH DIAGNOSTICS AND DEVICE

ESTHER YANG
Medical Device Consultant

KYUNG KIM
Engineer, Abbvie

JONGHYE WOO
Associate Professor of Radiology,
Harvard Medical School

KWANGMIN SON
CEO, PhAST

SCIENTIFIC SESSION SPEAKERS

ANTHONY LEE
Sr. Director,
Quantitative Pharmacology & Disposition, Seagen

DAEYEON LEE
Professor of Chemical Eng. and Biomolecular Eng.,
Univ. of Pennsylvania

HAKHO LEE
Associate Professor of Biomedical Engineering,
Harvard Medical School

TAEKYOUNG KWAK
Scientist, BostonGene

JUNGHEE SUH
Global Medical Information Leader,
Foundation Medicine, Genentech

NARA SHIN
Program Alliance Manager/MSL,
BostonGene

BUSINESS DEVELOPMENT PANEL DISCUSSION

SEHYUN (JASON) KIM
Director of BD&L, Merck

JOON JIN
SVP of Bio BD,
Bioluminescence Ventures/Hanwha Impact

DAE GON HA
Director,
Biotechnology Equity Research, Stifel Financial Corp.

MINJI KIM
CEO,
Cross Border Partners, LLC

REGISTRATION NOW OPEN

SPONSORED BY

YUHAN
KAIST
KMEDI hub
Daegu-Gyeongbuk Medical Innovation Foundation
KHIDI Korea Health Industry Development Institute
BATAVIA biosciences
ILDONG 일동제약
KSEA
GNTPharma 지엔티파마
labcorp Drug Development
XtalPi
ablbio
CURACHEM
Cyrus Therapeutics
DONG-A ST
Huons
samyang
WOOJUNGBIO



The Way of Yuhan

Yuhan Corporation, a group loved by the people and grown together with the people
For the last 90 years, the corporate culture of honesty and integrity,
and the strong beliefs in social responsibility are what made Yuhan what it is today.

Looking back on the path that we moved on and thinking of the path ahead,
Yuhan will make the leap as a global pharmaceutical company through innovative new drug development,
and by enabling healthiness and happiness for all the people in the world.

In the next 100 years, Yuhan Corporation will follow the noble spirit of our founder, Dr. New Ilhan,
and write the history of challenge and development moving forward.

Our challenge has already begun.

YUHAN

K-MEDI hub가 의료연구개발을 향해 큰 걸음을 내딛습니다.

발전과 혁신을 통해 미래를 선도하는 대한민국 의료산업의 허브
대구경북첨단의료산업진흥재단 K-MEDI hub가 함께 하겠습니다!

Korean American Society in Biotech and Pharmaceuticals
재미한인제약인협회

2023
KASBP SPRING SYMPOSIUM
YG CAREER DEVELOPMENT SESSION

This session will be divided into three groups (Government/Industry/Academia) offering you the opportunity to freely ask questions, engage in discussions, and receive advice from professionals.

Government

Sungyong Hwang, PhD

Sangwon Lee, PhD

Industry

Junghae Suh, PhD

Biogen - VP

Miyoun Hong, PhD

Labcorp - Director, Business Development

Academia

Hailey Choi, PharmD

Associate Professor - MCPHS University

Register here:

Date: June 2, 2023 (Friday)

Time: 4:00 PM ~ 5:30 PM

The Westin Waltham Boston
70 Third Ave, Waltham, MA
02451

Welcome Letter

We would like to welcome you to the "**2023 32nd KASBP Spring Symposium**".

Korean-American Society in Biotech and Pharmaceuticals (KASBP) is a premier professional organization with more than 2500 members from biotechnology, pharmaceutical, and academic institutions in both US and Korea. Our mission is to promote scientific information exchange, collaboration, and networking between research scientists, entrepreneurs, and undergraduates / graduate students.

This 2023 Spring Symposium focuses on the **Expansion of drug research & development in combination with diagnostics and devices**. As KASBP has hosted many scientific symposiums over the last 8 years, we have witnessed great evolution in the fields of drug research and development. Last year, a product applying precision medicine was launched in the US market after the concept was first presented at the 2015 KASBP Spring Symposium. To make this happen, many people from different disciplines were involved, and indeed, the alignment between scientific direction and business development strategy was especially important for the acceleration of the launch. This spring symposium, KASBP looks forward to discussing what new products are now available, what we expect to see in the pipeline, and how scientists can collaborate with our business partners to enhance drug discovery & development for challenging targets, and invites prominent speakers from industry, FDA, and academia. We are very pleased to have a chance to host such distinguished speakers and panels.

On June 2nd, the symposium will start at 6:00 PM (EST), the Symposium will open with a **Medical Device, Diagnostic Panel Session**. At the symposium, you will meet industry professionals as well as academic scientists. The following day will begin with scientific sessions, emerging K-Biotech, KASBP fellowship award, poster presentations, and BD Panel session.

We are confident that 2023 KASBP Spring Symposium offers a productive and memorable experience for each of you. In addition, We would like to express our most profound gratitude to the organizing committees, volunteers, and generous support from all sponsors for their dedication.

June 2nd, 2023

KASBP President Seungwon Chung
KASBP President Designate/Program Chair Ik-Hyeon Paik
2023 32nd KASBP Spring Symposium Organizing Committee

2022 – 2023 KASBP Officers

Title	Name	한글 이름	Affiliation
President	Seungwon Chung	정승원	AbbVie
President Designate	Ik-Hyeon Paik	백익현	Wave Life Sciences
General Director I	Sungkwon Kim	김성권	Alexion
General Director II	Kern Chang	장건희	Janssen R&D
Fellowship Director	Hyungwook Lim	임형욱	Novartis
Financial Director	Hyunkyung Jung	정현경	Medic Life Sciences
Public Relations Director	Kern Chang	장건희	Janssen R&D
Technical Director	Dooyoung Lee	이두영	Morphic Therapeutic
	Deaho Lee	이대호	Montefiore Medical Center
Web Director	Hyelim Kim	김혜림	PineTree Therapeutics
Career Development Director	Jooyoung Lee	이주영	Vertex Pharmaceutical
	Meena Choi	최미나	Genentech
Member Networking Director	Sung-Yong Hwang	황성용	
Sponsorship Director	Sungki Kim	김성기	Massachusetts Biomed Lab
Membership Director	Jeemin Yoo	유지민	Northeastern University
YG Director	Hyun Jin Jung	정현진	Columbia University
Legal Director	Elizabeth Lee	이엘리자베스	Lucas & Mercanti, LLP
Graphic Designer	Jamie JiYoung Park	박지영	Merck
	Lauren Kim	김로렌	AbbVie
Boston Chapter President	Dae-Shik Kim	김대식	Eisai
Connecticut Chapter President	Sung-Kwon Kim	김성권	Alexion
Illinois Chapter President	Kyung Hyo Kim (interim)	김경효	AbbVie
New Jersey / New York Chapter President	Eunchan Park	박은찬	GNT Pharma
Philadelphia Chapter President	Kern Chang	장건희	Janssen R&D
San Diego Chapter President	Hyun-Bae Jie	지현배	Levatio Therapeutics
San Francisco Chapter President	Oh Kyu Yoon	윤오규	Gilead Science
	Claire Jeong	정가영	Genentech
Washington DC Chapter President	Sung-Yong Hwang	황성용	
Councilor – Finance/legal	Yun H. Choe	최윤	ArentFox Schiff LLP
Councilor - Grant	Hak-Myung Lee	이학명	Shire
Councilor - Auditing	Sungtaek Lim	임성택	Sanofi
Councilor - Outreach	Young-Choon Moon	문영춘	PTC Therapeutics
Councilor – Chair, Advisory Committee	Yun H. Choe	최윤	ArentFox Schiff LLP
Advisory Committee	Past KASBP Presidents		

Floor Plan



Main Events (Fri, Sat): **Eden Vale Ballroom**
Poster Session (Sat): **Hallway #### area**
YG session (Fri): **Emerson**
Job interview / Company Private meeting room (Fri, Sat): **Livermore and Garfield**
Staff room (Fri, Sat): **Wellington**

Booths Location



Please use only the *** area**
Do not block any doors!
First come first serve, no assigned location

Symposium Schedule details (U.S. Eastern TIME)

June 2-3, 2023, Friday – Saturday

Job Fair Organizer: Career Development Director, Meena Choi (Genentech) / Joo Young Lee (Vertex)
2:00 pm - 5:30 pm *Livermore and Garfield*

June 2, 2023, Friday

YG Event (Students/Young Professionals) - *Emerson*
4:00 pm - 5:30 pm Moderator: KASBP YG Director, Hyunjin Jung, PharmD

Registration and Networking
4:00 pm - 6:00 pm Coordinator: Richard Sung Ki KIM, Massachusetts Biomed Lab

Opening & Congratulatory Remarks and Dinner - *Eden Vale Ballroom*
6:00 pm - 7:30 pm Moderator: KASBP President Designate, Ik-Hyeon Paik, Wave Life Sciences

- **Opening Remark** KASBP President Designate, Ik-Hyeon Paik, Wave Life Science
- **Congratulatory Remarks:** Yuhan, KHIDI, KAIST-GCC, K-Medihub
- **Dinner**

Keynote Panel session - *Eden Vale Ballroom*
7:30 pm - 8:45 pm Moderator: Esther Yang, (Former Abbott Laboratory Executive Director) / KASBP Illinois Chapter, Kyung Kim, (AbbVie)

***Panel: Esther Yang**, (Former Abbott Laboratory Executive Director), **Kwangmin Son**, (CEO, PhAST), **Jonghye Woo**, (Associate Professor of Radiology, Harvard Medical School),*
***Kyung Kim**, (Senior Scientist II, AbbVie)*

Sponsor Presentation I (Diamond/Platinum and Gold Sponsor) - *Eden Vale Ballroom*
8:45 pm - 9:40 pm Moderator: KASBP Philadelphia Chapter, Kern Chang, Janssen R&D

- **Yuhan: Yuhan's Global Open Innovation**
  Taejin Yoon, Executive Director, Head of Corporate Strategy Group
- **Ildong: Ildong's Five-Year of Drastic Transformations into an Innovative R&D Company**
  Alan Choi, R&D President
- **GNT Pharma: Perseverance and Resilience in Developing Therapeutics for CNS Disorders**
  Eunchan Park, Executive Director
- **Dong-A ST: New Flow, New Shift!**
  Eun-ju Ryu, COO, Dong-A America & Head of Dong-A ST Open Innovation Center

Group Networking - *Eden Vale Ballroom, Emerson, Livermore, Garfield*
9:40 pm - 11:30 pm Coordinator: KASBP Washington DC Chapter President, Sungyong Hwang

- **NW-01: Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology**
  (Moderators: Dae-Shik Kim, Eisai US; Ik-Hyeon Paik, Wave Life Sciences)
- **NW-02: Immunology-Oncology / Autoimmune / Inflammatory Diseases**
  (Moderators: Hyungwook Lim, Novartis; Hakryul Jo, Kymera Therapeutics)
- **NW-03: Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases**
  (Moderator: Nicholas (Nae Gyune) Rim, Novartis)
- **NW-04: Infectious Diseases / Vaccines / RNA Therapeutics**
  (Moderator: Taesun Eom, Beam Therapeutics)
- **NW-05: Neurological Disorders / Alzheimer's Disease / Parkinson's Disease / Aging**
  (Moderator: Jeonghoon Choi, Wave Life Sciences)
- **NW-06: Cell and Gene Therapy / Rare Diseases**
  (Moderator: Jooyoung Lee, Vertex Pharmaceuticals)
- **NW-07: Business Development / Venture Capital / Entrepreneurship / Legal / Consulting / Government Relations**
  (Moderators: Sehyun Kim, Merck;
  Eunchan Park, GNT Pharma;
  Minji Kim, Cross Border Partners, LLC)
- **NW-08: Bioinformatics / A.I. / Machine Learning / Quantitative Science**
  (Moderator: Ted Hong, AstraZeneca)
- **NW-09: Digital Health / Digital Therapeutics**
  (Hyungjin Yun, Boston University)
- **NW-10: CMC / Quality Assurance / Regulatory Affairs / Project Management**
  (Moderator: Yong Cho, YG Consulting)
- **NW-11: Medical Device / In Vitro Diagnostics / Biomedical Engineering / Analytical Method Development**
  (Moderator: Stephen Kim, Qiagen)
- **NW-12: Clinical Trial & Development / Clinical Pharmacology / Biostatistics**
  (Moderator: Chongwoo Yu)

June 3, 2023, Saturday

Registration and Breakfast - *Eden Vale Ballroom*
7:00 am - 8:00 am

Scientific Session A (Academic Research on Device and Diagnostics) - *Eden Vale Ballroom*

8:00 am - 09:00 am Moderator: KASBP NJ/NY Chapter, Eunchan Park, GNT Pharma

A-1: Factory-on-a-Chip: Scaling-up Droplet Microfluidics for Large-scale Pharmaceutical Particle Synthesis
Daeyeon Lee, Professor of Chemical and Biomolecular Engineering, University of Pennsylvania

A-2: Developing Biosensors for Clinical Applications – Lessons Learned and Challenges Ahead
Hakho Lee, Associate Professor of Biomedical Engineering, Harvard University

Emerging K-Biotech 1 (KAIST-GCC) - *Eden Vale Ballroom*
9:00 am - 10:00 am Moderator: KASBP San Francisco Chapter, Jin-Hwan Han, Merck

- **G2GBIO: Novel Long-Acting Microsphere by InnoLAMP Technology**
  Heeyong Lee, CEO
- **Prestige Biologic: Prestige Biologics Seeking Insight for a Successful Market Entry into the US for the Biomanufacturing Industry**
  Michael J. Kim, CFO
- **Wiregene Inc.: Innovative Technologies for Spinal Cord and Peripheral Nerve Regeneration**
  Jung Keun Hyun, Co-CEO
- **Biotoxtech: Specializing in IND-Enabling Studies: BTT Group, a Premier Integrated non-clinical CRO**
  Jinju Lee, Team Leader
- **CUePEAK BIO: Development of Precision Medicine for Patients with Atopic Dermatitis**
  Joonsung Hwang, CEO

Coffee Break 10:00 am - 10:15 am

Emerging K-Biotech II (K-MediHub) - *Eden Vale Ballroom*

10:15 am - 11:00 am Moderator: KASBP Illinois Chapter, Grace Kim, AbbVie

- **Txinno Bioscience: Introduction of Txinno Bioscience and TXN10128 as an Innate Immune Modulator**
  Jong Heun Lee, CDO
- **Calici Co.: Open Drug Discovery Platform, Pharmaco-Net: A New Horizon for New Drug Development Based on Protein Structure**
  Young Bin Park, CSO
- **VS PharmTech: Better Life of Patients with Cancer**
  Hye Kyung Choi, CBO

Sponsor Presentation II (Gold Sponsors) - *Eden Vale Ballroom*
11:00 am - 11:30 am Moderator: KASBP Boston Chapter, Dae-Shik Kim, Eisai

- **Xtalpi**
  How Artificial Intelligence Enhances Drug Discovery
  Sang Eun Jee, Application Scientist
- **Batavia Bioscience**
  High Cell Density and Cost-Effective Manufacturing of Viral Vectors
  Peter Abbink, Managing Director

Award Ceremony and Presentation - *Eden Vale Ballroom*
11:30 am - 12:00 pm Moderator: KASBP Fellowship Committee, Sejong Chun, Novartis

- **KASBP-Yuhan Awardees (3)**
- **KAIST-GCC (1)**
- **K-MediHub (1)**

Group Photo
12:00 pm - 12:15 pm

Lunch, Poster session and Networking - *Eden Vale Ballroom, Hallway*
12:15 pm - 02:00 pm

Scientific Session B (Drug Discovery and Companion Diagnostics) - *Eden Vale Ballroom*
02:00 pm - 03:30 pm Moderator: KASBP San Diego Chapter, Dong Jun Lee, Adcentrx Theraputics

B-1: ADME in Drug Development: Understanding the Fate of Drug in Human
Anthony Lee, Senior Director, Seagen Inc.

B-2: The Role of Circulating Tumor DNA in Oncology Drug Development
Junghee Suh, Global Medical Information Leader, Genentech

B-3: Growing Trend of Precision Medicine in Cancer Care
Taekyoung Kwak, Scientist, BostonGene / Nara Shin, Program Alliance Manager/MSL, BostonGene

Coffee Break 03:30 pm - 03:45 pm

KHIDI - Business and Development Panel Session - *Eden Vale Ballroom*

03:45 am - 05:00 pm Moderator: Sehyun Kim, Merck

Panel: Minji Kim *(CEO, Cross Border Partners, LLC),* ***Sehyun Kim*** *(Director BD&L, Merck),*
Joon Jin *(Biotech BD Director, Bioluminescence Ventures/Hanwha Impact),*
Dae Gon Ha *(Director, Biotechnology Equity Research/Stifel Financial Group)*

5:00 pm - 5:15 pm **Closing remarks**

KASBP 19th President, Seungwon Chung, AbbVie

5:15 pm - Dinner, Networking (registration required)

Sponsor Presentation III (Silver Sponsors) - *Eden Vale Ballroom*

6:00 pm -

- **Huons Inc.**
  Jay Choi, CEO Huons USA
- **Woojung Bio**
  Heejung Chun, BD Team Leader
- **Samyang Holdings, Inc.**
  Seyoon Kim, BD Team Manager
- **Cyrus Therapeutics**
  Wooseok Han, Executive Vice President
- **Curachem, Inc.**
  Sook Jung Shin, CEO

Medical device, Diagnostic Panel Session

Esther Yang

Former Abbott Labs

aesuh51@gmail.com

BS in Chemistry at the University of Massachusetts Amherst, PhD in Biophysical Chemistry at UC Berkeley, and Postdoc in Biophysics at the University of Pennsylvania. More than thirty-five years of Diagnostics industry experience, 14+ yrs in Medical Products, DuPont, 2 yrs at Sanofi now Beckman, and 19+ yrs at Abbott Labs. Since retirement, worked at a startup operation in Silicon Valley for 9 mo, and consulted for a mid-size diagnostics company in Korea for 2 yrs. Led and built teams in US, Germany, Japan, and China to enable new technology scouting, discovery research, product development, commercialization and full product life cycle management. At Abbott Park, established immunoassay menu pipeline in targeted disease areas (Cardiac, Cancer, Diabetes, Infectious Disease). In Dallas, two new instrument systems were launched in partnership with Toshiba and over 100 Clinical Chemistry assays were launched working with 10 global reagents suppliers. Implemented overhauled Quality System to fully comply with FDA regulations. Built an organization of up to 150 scientists and engineers. Abbott Clinical Chemistry business grew from $50M to >$500M. Established new R&D Center in Shanghai in 2014. Led a global R&D organization that delivered cost effective diagnostic solutions through smart exploitation of leading-edge technologies in partnership with global suppliers.



Jonghye Woo

Massachusetts General Hospital and Harvard Medical School

jwoo@mgh.harvard.edu

Prof. Woo is an Associate Professor of Radiology at Harvard Medical School and a Faculty Member at the Gordon Center for Medical Imaging, Massachusetts General Hospital. His research centers on developing and applying innovative (1) magnetic resonance imaging techniques and (2) artificial intelligence (AI)-based solutions to enhance image quality, analysis, and interpretation, and ultimately to improve diagnosis, prognosis, and treatment for various disorders. He earned his B.S. degree from Seoul National University, South Korea, in 2005, followed by M.S. and Ph.D. degrees from the University of Southern California (USC), Los Angeles, in 2007 and 2009, respectively, all in Electrical Engineering. In 2009, he interned at Philips Research North America in Briarcliff Manor (now in Cambridge), and in 2010, he was a Research Associate at Cedars-Sinai Medical Center in Los Angeles. From 2010 to 2014, he was a Postdoctoral Researcher and later a Faculty Member at the University of Maryland and Johns Hopkins University in Baltimore. He has received numerous accolades, such as a scholarship from the Korean government, the USC Viterbi School of Engineering Best Dissertation Award, and the NIH K99/R00 Pathway to Independence Award. He has served on various NIH study section panels, such as the NIH Small Business Innovation Research (SBIR/STTR), NIH Bridge2AI Other Transaction, and NIH Human Biomolecular Atlas Program. He has also been an Editorial Board Member and Program Committee for several journals and conferences. He is a Senior Member of IEEE, a Life Member of SPIE, and a member of MICCAI, ISMRM, SNMMI, and AAAS.

Kwangmin Son

PhAST Corp.

kwangms@gmail.com

Dr. Kwangmin Son is the co-founder and CEO at PhAST. He is responsible for setting the vision of the company and for the overall execution of the company's clinical development, business plan and strategic partnerships that align with the company's strategy and product vision. Dr. Son is a recognized healthcare technology expert within the industry and was invited to present to the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) at the Department of Human and Health Services, at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022), and at the Infectious Diseases Society of America (IDSA)'s IDWeek 2022. Dr. Son received a PhD in Engineering from Massachusetts Institute of Technology (MIT), and a Bachelor of Science and Master of Science degrees in Engineering from Seoul National University in South Korea.

Kyung Kim

AbbVie

Kyung.Kim@abbvie.com

Ph.D. in Chemical Engineering at the University of Illinois at Chicago. Engineer with 10+ years of competitive experience in a wide range of duties related to medical research methodologies and applications in both research and clinical environment, including 7+ years at AbbVie. Knowledge of utilizing diverse engineering skills, clinical research, and advanced academic training in compliance with governing procedures. Responsible for developing verification strategies and documentation, coordinating studies, and executing investigations and issue resolutions for drug-delivery devices. Supported lab capabilities as an SME for equipment/software qualification, test method development & validation, and lab training. Experiences in Data Science and Machine Learning give a running start to future AI integration and machine learning in medical devices.

Scientific Session A



Daeyeon Lee

University of Pennsylvania

daeyeon@seas.upenn.edu

Factory-on-a-Chip: Scaling-up Droplet Microfluidics for Large-scale Pharmaceutical Particle Synthesis

Despite some successes in translating microfluidic-based assays and diagnostics to commercial technologies have been achieved, few examples of such translations in the domain of materials manufacturing based on microfluidics have been accomplished, largely due to the very low throughput of droplet/bubble generations. Without solving the scale-up challenge, microfluidic-based materials synthesis will continue to remain an academic exercise that may not reach its true potential. In this talk, I will present the recent developments that the Issadore and Lee Groups at the University of Pennsylvania have made in enabling large-scale manufacturing of nano/microparticles using microfluidics. By parallelizing flow focusing generation units coupled with flow resistors in solvent-resistant materials, microfluidic generation of droplets and bubbles with precisely controlled size and morphology has been achieved at the liters-per-hr scale. Critical issues in enabling scale-up and outstanding challenges in future development of the scale-up devices will be discussed.

Daeyeon Lee is Evan C. Thompson Endowed Term Chair for Excellence in Teaching and Professor in Department of Chemical and Biomolecular Engineering at the University of Pennsylvania. He received his BS in Chemical Engineering at Seoul National University and PhD in Chemical Engineering at Massachusetts Institute of Technology. His research focuses on developing deep understanding of the interactions between soft materials near or at interfaces and extending the obtained knowledge to direct the assembly of macroscopic structures that have designed properties and functionality. He has won numerous awards including the 2010 Victor K. LaMer Award, NSF CAREER Award, 2013 3M Nontenured Faculty Award, 2013 AIChE NSEF Young Investigator Award, 2014 Unilever Award for Young Investigator in Colloid and Surface Science and 2017 Soft Matter Lectureship Award.

Hakho Lee

Massachusetts General Hospital / Harvard Medical School

hlee@mgh.harvard.edu

Developing Biosensors for Clinical Applications – Lessons Learned and Challenges Ahead

Highly sensitive, fast, and cost-effective diagnostic systems can have far-reaching applications in medicine and the life sciences. At our laboratory, we are committed to advancing the field of diagnostics by harnessing the latest breakthroughs in nanomaterials, biophysics, electronics, and computation. Our ultimate goal is to create diagnostic platforms that are not only reliable and accurate but also accessible to individuals and communities around the world. This presentation will highlight some of our most recent research efforts. Specifically, we will discuss how we have developed integrated biosensors to rapidly detect disease markers in bodily fluids (e.g., blood, saliva, and urine). We will also discuss major technical challenges in translating these sensors into clinical applications.

Dr. Lee has extensive experience in nanomaterials, biophysics, microfluidics, and electrical engineering. His research focuses on developing novel biomedical sensors for clinical applications, for example, the world's smallest portable NMR device, integrated circuit (IC) chips for cancer cell detection, and a point-of-use device for allergen detection. Many of these systems have been translated into clinical applications. Dr. Lee's group also pioneered new analytical tools for infection diagnostics, including PAD (polarization anisotropy detection), ultrafast nanoPCR, and integrated

biosensor for sepsis. He earned his B.S. degree from Seoul National University, South Korea, in 1998, followed by Ph.D. degrees from the Harvard University, Cambridge, Massachusetts, in 2005. Dr. Lee currently directs the Biomedical Engineering Program at the Center for Systems Biology (MGH) since 2010 and is also a Hostetter MGH Research Scholar since 2017.

Emerging K-Biotech Session I

Developed a global technology commercialization support system for emerging countries focusing on ICT and scientific technology fields to enhance technology transfer in developing countries.

Emerging K-Biotech Session I

Company	대표	Technology (Product)	Home page	설립
G2GBIO	이희용	장기지속형 미립구 주사제 개발	http://www.g2gbio.com	2017
Prestige Biologic	현덕훈	항체 및 유전자 재조합 단백질 바이오의약품 제조 CDMO	https://prestigebiologics.com/eng/main	2015
WIREGENE	현정근, 윤상진	의료용 소재 - 말초/척수용 인공 신경도관	http://www.wiregene.com/	2021
Biotoxtech	강종구	비임상 안전성 평가, 유효성 및 약리 평가, 신약개발 컨설팅 등	https://www.biotoxtech.com/	2000
CUePEAK BIO	황준성	아토피 피부영 정밀의료화: 병인기반 맞춤신약과 동반진단	https://cuepeakbio.com/	2020

Emerging K-Biotech Session II

Daegu-Gyeongbuk Medical Innovation Foundation

To become a global R&D business hub leading the world's advanced healthcare industry by 2025

Emerging K-Biotech Session II

Company	대표	Technology (Product)	Home page	설립
Txinno Bioscience	박찬선	저분자 혁신 항암제 개발 전문	https://txinno.com/?act=main	2018
Calici Co.	최재문	신약/기능성물질발굴 플랫폼 (IT) 항바이러스제개발, 신약개발, 축산업, 기능성원료, 배양육등 (BIO)	https://calici.co/	2018
VS PharmTech	박신영	항암치료제 개발	https://www.vspharmtech.com/	2018

Scientific Session B

Anthony J. Lee

Seagen Inc.

jyantonio@gmail.com

ADME in Drug Development: Understanding the Fate of Drug in Human

Understanding absorption, distribution, metabolism, and excretion (ADME) properties of drug candidates is essential for the successful discovery and development of new therapeutic agents. Among various ADME studies, starting from in vitro metabolic stability in early discovery to the radiolabeled human mass balance study in late clinical development, quantitative and qualitative analyses of drug-related components in the systemic circulation provide critical information required for thorough evaluation of safety and efficacy of drug candidates. During the process, unexpected issues or late findings may arise and failure to resolve them may have consequences such as delay or refusal from the health authority. A couple of recent war stories involving ADME questions encountered during drug development will be shared in this presentation.

Anthony J. Lee is a Senior Director, Head of Translational ADME and PKPD in the Department of Quantitative Pharmacology and Disposition at Seagen, formerly known as Seattle Genetics. His team focuses on nonclinical pharmacokinetics and metabolism, mass spectrometric bioanalysis, biophysics and mechanistic modeling, translational Pharmacokinetics/Pharmacodynamics, and drug interactions in support of early- and late-stage oncology drug candidates including antibody-drug conjugates (ADCs), therapeutic proteins, and small molecules. Prior to joining Seagen in 2017, Anthony worked in the Department of DMPK at AbbVie for 12 years. He received his PhD in Pharmaceutical Sciences from the University of South Carolina in 2003, followed by two years of post-doctoral training at the University of Michigan Medical School. He worked for Samyang Corp. in the field of Drug Delivery System before coming to the United States.



Junghee Suh

Genentech

junghee.suh@gmail.com

The Role of Circulating Tumor DNA in Oncology Drug Development

Targeted therapies have revolutionized cancer treatment, and identifying targetable genomic alterations is key to improving patient outcomes. Liquid biopsy (LBx) using circulating tumor DNA (ctDNA) offers a minimally invasive approach to assess diagnostic and prognostic information in cancer patients, complementing traditional tissue-biopsy testing. LBx applications include treatment selection, identification of drug-resistant mutations, disease progression and treatment response tracking, minimal residual disease monitoring, surveillance, and multi-cancer early detection. Currently, LBx is used as a companion diagnostic (CDx) for multiple oncology therapeutic products, primarily in advanced stages of cancer, with an expanding list of CDx. In the early stages of cancer, ctDNA is being explored as a biomarker that may expedite drug development. This presentation covers ctDNA-based LBx for treatment selection and monitoring, including examples of case clinical studies.

Junghee Suh is a Global Medical Information Leader focusing on Foundation Medicine products at Genentech. She holds a Bachelor's and Master's degree in Biological Science from Seoul National University, and a PhD in Molecular Genetics and Genomics from Washington University School of Medicine. Her research focus has been human genetic disorders, which she continued in her postdoctoral training at Harvard Medical School. With a desire to apply advanced scientific technologies to real-world clinical practice, she joined Roche medical affairs team in 2017 as a medical manager and transitioned to a global role at Genentech in 2019. In her current position, she educates healthcare professionals and supports customers' complex medical inquiries from Roche networks. Her main interest lies in utilizing advanced technologies to improve patients' treatment journeys.

Taekyoung Kwak

BostonGene

Taekyoung.kwak@bostongene.com

Nara Shin

BostonGene

nara.shin@bostongene.com

Growing Trend of Precision Medicine in Cancer Care

Unprecedented biotechnological advancements have led to the opening of a new era for healthcare, especially in the oncology field. Genomic profiling and transcriptomic, proteomic analysis of each patient from tumor and liquid biopsy are indispensable “omics” technologies to lead to more precise, predictable, and optimized therapy. Artificial intelligence (AI) driven machine learning algorithm to vast data set is equal importance as the use of “omics” approaches have generated massive amounts of data sets, and their analyses. BostonGene’s state-of-the-art molecular testing has integrated next-generation sequencing technologies, including whole-exome and whole-transcriptome sequencing, multiplex immunofluorescence imaging, cell-free DNA/RNA, and flow cytometry. At the beginning, BostonGene’s decision tree machine learning algorithm, Kassandra has compiled more than 9,400 sorted samples of various cell populations to reconstruct virtual tumor microenvironments and has continuously acquired real-world clinical trials of responder/non-responder, longitudinal clinical datasets, cancer of unknown primary (CUP) cases to accurately assist treatment decision making. To overcome cancer complexity, notions of diagnosis and treatment need to be shifted from drug-centric to patient-centric personalized combination therapy. In KASBP Spring 2023 symposium, we will cover the design, advantages, limitation, and challenges in the era of precision medicine.

Dr. Kwak currently work at the immunology team of BostonGene as a Scientist II. He has over twelve years of experience in cancer and cancer immunology including five years of experience in immunotherapies under the mentorship of Dr. Dmitry I. Gabrilovich. In his postdoc training, he studied translational research for myeloid biology and clinical approaches for adaptive T cell therapies. This scientific experience had led him to position in BostonGene where provides comprehensive precision medicine, called Tumor portraitTM. He is leading a team of Heme cancer projects where not only generating immunoprofiling status of each patient’s PBMCs but also providing normal and tumor cell materials from same donor for whole exome and whole transcriptomic sequencing. Using our unique comprehensive analysis, our service integrates detailed information such as immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended treatments.

Dr. Shin is Program Alliance Manager and Medical Science Liaison (MSL) at BostonGene, a precision oncology company providing clinical and research solutions with multiple AI-based molecular and immune profiling techniques to understand the tumor, microenvironment, and host immunity. She is identifying and developing robust peer relationships with Key Opinion Leaders (KOLs) for scientific engagement and institutional partnerships. She has been successfully developing and managing collaborations in various cancer types including pancreatic, gastric, urothelial, cancer of unknown primary (CUP), prostate, kidney, sarcoma, and glioma with leading cancer

institutions and industry partners that have led multiple publications. This includes abstracts in AACR 2021, GI ASCO 2022, ASH 2022, AACR 2022, ASCO 2022, USCAP 2023, and AACR 2023, poster presentation in AACR 2023, and manuscript publication (Frontiers in Oncology 2022, Gastroenterology in revision). She has a broad background in precision oncology, immunology, and genetics, and several elements of training and expertise that allow me to successfully exchange medical and scientific knowledge with both internal and external stakeholders for product developments including identifying prognostic biomarkers and validating algorithms for CUP prediction. Her passion is to bridge the gap between ever fast growing scientific understanding (and related technologies) and healthcare.

KHIDI-BD Panel Session

Sehyun (Jason) Kim

Merck

Sehyn.jason.kim@gmail.com

Sehyun (Jason) Kim is a biomedical scientist and an experienced business developer with comprehensive understanding of the drug development and business development life cycle. His expertise lies in the fields of neuroscience, immunology, and cancer biology, which he honed through his academic training at the University of Oklahoma Medical Center, NYU Medical School, and Rockefeller University, and during his tenure as a research scientist at Genentech. MBA graduate at UC Berkeley with work experiences across big pharma and biotech, Sehyun carries out best practices in corporate strategy and business development as Director of BD&L at Merck Headquarters in Rahway, New Jersey.

Joon Jin

Hanwha Impact / Bioluminescence Ventures

joonjinpro@gmail.com

Joon joined Hanwha Impact as SVP of Bio Business Development in 2021 and serving as Partner at Bioluminescence Venture (BLV). At Hanwha and BLV, Joon has been involved with investments in Tessera Therapeutics, Cellarity, and other innovative biomedical companies. He also oversees in-licensing of early-stage biotechnologies from academia. Prior to Hanwha, he was the acting president of CJ Biomaterials, formerly Metabolix, where he oversaw R&D and business activities of the company in synthetic biology, microbiome, and exosome-based therapeutics as well as strategic equity investments. Joon holds a Ph.D. in cell and molecular biology from POSTECH, a B.S. from Seoul National University, and an M.B.A. from Boston University.

Dae Gon Ha

Stifel Financial

ha.daegon0525@gmail.com

Dae Gon Ha, Ph.D. is a Director and Senior Analyst covering the Biotechnology sector. He joined Stifel in 2020. Dae Gon was previously at BTIG, where he was Vice President and Senior Analyst covering Biotechnology. Prior to that, Dae Gon was Vice President at SVB Leerink (formerly Leerink Partners; currently SVB Securities) as part of the Biotechnolgy Equity Research team. Before making his transition into finance, Dae Gon was a postdoctoral research fellow at Harvard Medical School. He received his B.A. in Biology from Grinnell College and his Ph.D. in Microbiology/Immunology from the Geisel School of Medicine at Dartmouth.

Minji Kim

Cross Border Partners, LLC

kminji9331@gmail.com

Dr. Minji Kim is an advisor and company builder in life sciences with more than two decades of experience in corporate and business development, alliance management, commercial strategy, finance, operations, scientific research and company formation. She has extensive experience in start-up, mid-size public and private biotech companies in the US and China, and multinational pharmaceutical companies across broad therapeutic and technical areas, including oncology, CNS, ophthalmology, small molecule, biologics, medical device and digital medicine. With her broad deal experience, including both buy- and sell-sides, leading soup-to-nuts transaction processes, she consistently delivered transformative and profitable impact to biopharma companies, tripling company value, pivoting R&D directions, enabling equity financings with new strategic branding, and bringing $170 million upfront cash within less than 2 years through pharma partnerships. In addition, Minji uniquely provides global insights and network of industry partners and investors with her executive leadership experience at a global biotech company as well as her relationships with US, European and Asian life science professionals, which were established over time. Minji is currently President & CEO of Cross Border Partners, LLC, her consulting business to help start-ups and company formation efforts. Previously, she was Chief Business Officer at Affamed Therapeutics and General Manager at Affamed Digital, Head of BD and Alliance Management at Jounce Therapeutics, VP of Corporate and Business Development at Curis, Inc and Global Oncology BD & Licensing team at Hoffmann-La Roche. She obtained her PhD in Seoul National University in South Korea and MBA in Yale School of Management.

Fellowship Announcement

The Korean American Society in Biotech and Pharmaceuticals (KASBP) is cordially inviting you to apply for **KASBP Fellowship awards in the 2023 KASBP Spring Symposium** to be held In-Person from **June 2nd** (Friday) to **June 3rd** (Saturday) at The Westin Waltham/Boston. As an honored tradition, we award the fellowship to young scholars who demonstrated a proven record of important contributions to the field of biomedical and pharmaceutical research. The winner will receive $1000.

- **Invited Area:** Medical sciences, Biological & Pharmaceutical sciences, Organic/Medicinal chemistry, and/or areas related to drug discovery and development.

Detailed Information:

- **Qualification:**
  - **Postdoctoral fellow** (PhD, MD, PharmD, DVM, and/or MD/PhD) currently working at academic or pharmaceutical institution.
  - **Staff scientist** with either **doctoral degree or master degree** working at academic or pharmaceutical institution.
  - **Instructor or non-tenure track junior staff member** working at academic institution.
  - Graduate students are **NOT eligible** to apply.
- **Eligibility:** The fellowship awardee **must** register to the KASBP Spring Symposium to be eligible to receive the fellowship. Further details on the Spring Symposium registration will be announced.
  - **KASBP Support:** The awardee will receive shared-room hotel (1 night max) support and waiver of registration fee from KASBP headquarter (HQ), and potential travel support from KASBP local chapter.
- **Requirement:**
  - The awardee **must** give a 3-min oral talk and present a poster.
  - All applicants are **encouraged** to present posters. You will be notified the acceptance of poster presentation once selected.
- **Application Materials:** Abstract, Title, and CV
  - **Due date:** April 7th, 2023 (9 pm EST)
  - **Format:** Abstract, Title, and CV (combined PDF)
  - **Typeface:** Times New Roman, font size 11 or 12 points
  - **Abstract:** Concise (must include future direction)
  - **Send to:** KASBP Fellowship Committee,
  - E-mail: fellowship@kasbp.org

**Please contact the committee chair for any questions regarding the fellowship application*

2023 KASBP Spring Symposium Fellowship Committee

Job Fair Announcement

The KASBP Job Fair is an excellent opportunity to build connections between the qualified candidates and hiring companies for recruiting the talent.

Date: June 2nd, from 2:00 PM to 5:30 PM

Job Fair Requirement:

- 2023 Spring Symposium registration is required:
  - When you fill out the registration form, please select "Yes" in the Job Fair section.
- If you have already REGISTERED the symposium, but still want to participate Job Fair please follow this **LINK**
- To encourage participation, the registration fee for 2023 Spring Symposium will be reimbursed to the participants attending the symposium in person. Please visit the registration desk during check-in for a gift card!

Job Fair participant's responsibility:

- You will directly apply to the company/position based on the job posting instructions.
- If there is a match between an applicant and a company, the company will contact the applicant directly (*not through Job Fair team*).
- The company may contact the applicant first based on the submitted CV.

Company's responsibility:

- The company will have access to the CVs of *all* Job Fair participants.
- The company can contact individuals for potential recruitment.
- If there is a mutual interest, the company may set up a virtual interview. If an in-person interview is needed, the Job Fair team will help set up a schedule for time/room during the symposium. This should be notified to the Job Fair team in advance (3-4 weeks) to plan accordingly. (jobfair@kasbp.org)

2023 KASBP Spring Job Fair Participating Companies & Job Openings:

- HANALL BIOPHARMA
- Yuhan USA
- GNT Pharma
- Myriad Life Sciences
- MedySapiens
- Biotoxtech

2023 KASBP Spring Symposium Job Fair Committee

YG Program Announcement

As part of our YG program, we are pleased to announce a **Career Development Session** scheduled for Friday, June 2nd.

Career Development Session

For the upcoming Career Development Session, separate discussion tables will be prepared for three distinct career fields, namely Government, Industry, and Academia. Expert speakers will be accompanying each table to encourage YGs to participate actively, pose questions, and seek advice.
To further streamline the preparation, we are conducting a survey to ascertain our members' interests in their respective career fields. We have attached the survey link below and would greatly appreciate your participation.

Survey Link: https://forms.gle/hViFTopjAsAzrxHX8

We greatly appreciate your participation and interest in KASBP 2023 Spring Symposium and YG Programs. We will do our best to ensure YGs gain the maximum benefit from the event!

2023 KASBP Spring Symposium YG Program Committee

Poster Session

2023 Spring KASBP Fellowship Awardees

Award Name	Awardee	P-#	Affiliation
KASBP-YUHAN Fellowship	Sangwook Oh	P-1	University of Pennsylvania
KASBP-YUHAN Fellowship	Yoon Seok Kim	P-2	Stanford University
KASBP-YUHAN Fellowship	Dongsung Kim	P-3	Memorial Sloan Kettering Cancer Center
KASBP-KAIST GCC Fellowship	Hun-Goo Lee	P-4	Massachusetts General Hospital, Harvard University
KASBP-KMEDIHUB Fellowship	Jihye Park	P-5	Broad Institute

2023 Spring KASBP Poster Presenters

P-#	Presenter	Affiliation
P-6	Mikyung Kang	Massachusetts General Hospital at Harvard University
P-7	Seongmin Kim	Wyss Institute at Harvard University
P-8	Jeongin Son	Amgen at South San Francisco
P-10	Hong-Jai Park	Yale University
P-11	Ji Seul Han	Harvard University
P-12	Sungwook Jung	Brigham Women's Hospital at Harvard University
P-13	Young Bin Park	Calici Therapeutics Inc.
P-14	Joonsung Hwang	CUePEAK BIO. Co. Ltd.
P-15	Heeyong Lee	G2GBIO, Inc
P-16	Michael J. Kim	Prestige Biologics Co. Ltd.
P-17	Jung Keun Hyun	WIREGENE Co. Ltd.
P-18	Dong-Won Son	Biotoxtech

P-1: Precision targeting of antigen-specific B cells in MuSK myasthenia gravis with MuSK-CAAR T cells

Sangwook Oh, University of Pennsylvania

MuSK myasthenia gravis (MuSK MG) is a B cell-mediated autoimmune disease that causes life- threatening muscle weakness. Anti-MuSK autoantibodies disrupt AChR clustering and neuromuscular junction signaling. MuSK MG therapy with steroids and the anti-CD20 monoclonal antibody (e.g. rituximab) aims to suppress or eliminate antibody-producing B cells, although the disease often relapses due to incomplete B cell depletion, and even transient B cell depletion risks serious infections. The ideal therapy would eliminate only the autoantibody-producing B cells while preserving the other healthy B cells. Chimeric antigen receptor (CAR) T cells have transformed cancer treatment by engineering T cells to eradicate B cell cancers, raising the feasibility that precision medications can be extended to other B cell-mediated diseases such as MuSK MG. By expressing the MuSK autoantigen as the extracellular receptor domain of a CAR (called a chimeric autoantibody receptor (CAAR)) with 4-1BB/CD3ζ cytoplasmic signaling domains, we genetically engineered human MuSK CAAR T cells (MuSK-CAART) to selectively kill MuSK-reactive B cells expressing anti-MuSK B cell receptor (BCR) on the surface. We demonstrate that MuSK-CAART can kill B cells targeting a broad range of physiologic MuSK epitopes. MuSK-CAART exhibited comparable efficacy as anti-CD19 CAR T cells in eliminating anti-MuSK B cells in immunodeficient NSG mice xenografted with anti-MuSK BCR^+ Nalm6 cells, in the presence or absence of soluble anti- MuSK antibodies. In an immunocompetent experimental autoimmune MG model using mouse CA(A)R T cells, anti-CD19 CAR T cell treatment depleted $CD19^+$ B cells and decreased both serum anti-MuSK IgG and total IgG levels, whereas murine MuSK-CAART comparably decreased anti-MuSK IgG titers without affecting total B cells or serum IgG levels, reflecting specific depletion of rare MuSK-reactive B cells (<2% in total B cells). Toxicology studies in the NSG xenograft model and screens of a high-throughput human membrane proteome array and primary human tissues did not identify off-target cytotoxicity of MuSK-CAART.

These data partly formed the basis of an investigational new drug application for MuSK- CAART, which has been allowed by the FDA for the treatment of MuSK MG. Future studies will focus on the improving MuSK-CAART clinical outcomes including increased sensitivity of MuSK-CAART against low-affinity B cell clones and long-term persistence.

P-2: Structure-guided design of optogenetic tools with properties enabling markedly improved optogenetic control in the brain

Yoon Seok Kim, Stanford University

The recently discovered pump-like channelrhodopsins (PLCRs), including ChRmine and KCRs, exhibit puzzling properties (unusually-large photocurrents, extreme light-sensitivity, and exclusive ion selectivity to monovalent cations) that have opened up new opportunities in optogenetics. Although PLCRs have gained broad interest and application in neuroscience research (since Marshel et al., ***Science*** 2019), little is known about the molecular mechanisms by which these unusual channelrhodopsins operate. Structural mechanisms and structure-guided engineering of channel conduction, light sensitivity, and speed in this family of proteins would likely lead rapidly to creation of powerful new resources for optogenetics. Here we present several designed PLCRs based on our recently-published high-resolution cryo-electron microscopy structures (Kishi*, Kim* et al., ***Cell*** 2022, Tajima*, Kim* et al., 2022). The structure reveals novel architectural features including the retinal binding pocket, ion conduction pathways and putative selectivity filters, which enabled us to engineer variants with red-shifted action spectra, faster- and slower-closing kinetics, and markedly-changed ion selectivity. Our structure-based design of PLCRs will open the door to diverse applications in neuroscience and point the way toward further structure-guided creation of novel channelrhodopsins for optogenetic applications across biology.

P-3: Pan KRAS inhibitor selectively inactivates oncogenic signaling and tumor growth

Dongsung Kim, Memorial Sloan Kettering Cancer Center

KRAS is one of the most mutated proteins in cancer and efforts to directly inhibit its function have been ongoing for decades. The most successful of these efforts has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumor growth in patients. Whether inactive state selective inhibition can be employed to therapeutically target non-G12C KRAS mutants remains under investigation.

Here we report the discovery and characterization of a non-covalent inhibitor that binds preferentially with high affinity to the inactive state of KRAS, while sparing NRAS and HRAS. Although limited to only a few amino acids, the evolutionary divergence in the GTPase domain of RAS isoforms was sufficient to impart orthosteric and allosteric constraints for KRAS selectivity. The inhibitor blocked nucleotide exchange to prevent the activation of wild-type and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. Inhibition of downstream signaling and proliferation was restricted to cancer cells harboring mutant KRAS and drug-treatment suppressed KRAS mutant tumor growth in mice, without having a detrimental effect on animal weight. Our study suggests that most KRAS oncoproteins cycle between an active and inactive state in cancer cells and are dependent on nucleotide exchange for activation. Our study serves as a blueprint for the development of additional KRAS directed therapeutics, including small molecule inhibitors of GTP-bound KRAS and proteolysis targeting chimeras. Pan KRAS inhibitors, like the one described here, merit clinical testing in patients as they stand to impact the clinical outcomes of patients with KRAS-driven cancers, including those with lung, colorectal and pancreatic cancer as well as additional less frequent cancer types. Selective inhibition of KRAS, while sparing HRAS and NRAS, a property that differentiates our inhibitor from other emerging drugs, is likely to produce a wide therapeutic index in the clinic.

P-4: Developing novel therapeutic methodologies for Fragile X syndrome by reactivating FMR1 and contracting CGG repeats via small molecule treatment

Hun-Goo Lee, Massachusetts General Hospital at Harvard University

Fragile X syndrome (FXS) is one of the most common monogenic causes of autism spectrum disorders (ASD). Here I describe potential methods for correcting the genetic cause of FXS without introducing gene-editing nucleases in cellular models. In FXS patients, very long expansion of CGG trinucleotide repeats (>200 times) at the 5' UTR of the FMR1 gene causes epigenetic silencing of FMR1, a crucial gene for brain development. By investigating conditions favorable to FMR1 reactivation, I have found that certain sets of small molecules can strongly reactivate FMR1 mRNA and FMRP expression in human embryonic stem (ES) and induced pluripotent stem (iPS) cells with FXS full mutation. Surprisingly, it also entails the shortening of the long CGG repeats. I traced the mechanism to a site-specific R-loop — a 3-stranded RNA-DNA structure — that is both necessary and sufficient for repeat contraction. The R-loop formation triggers DNA demethylation and FMR1 transcription, which in turn fortifies R-loop formation. Repeat contraction is specific to FMR1, restores production of FMRP protein. Collectively, these data implicate a positive feedback loop of DNA demethylation, de novo transcription, R-loop formation, and DNA repair in CGG contraction and FMR1 reactivation. (Lee *et al*., Cell in press) By identifying the mechanisms of CGG repeat expansion/contraction and epigenetic mis-regulation in FXS, I plan to develop novel therapeutic methods of permanently reactivating *FMR1* genes in FXS cells by inducing CGG repeat contraction without the use of an exogenous editing system (e.g. CRISPR). As FXS cellular phenotypes could be reversed with *FMR1* restoration, the proposed work can contribute to FXS therapeutic developments by uncovering safe ways to restore *FMR1* in the FXS patient cells using small molecules that target the identified epigenetic regulators. In addition, an approach to treating FXS in the future could involve targeting the non-canonical DNA/RNA secondary structures by CGG repeats for repeat contraction and re-expression of the *FMR1* in FXS patient cells. These approaches for FXS therapeutics are innovative because (i) the treatment is based on re-awakening the native *FMR1* gene carried within the patient's own cells by cell-intrinsic mechanisms, (ii) *FMR1* reactivation strategy is based on removing the root cause by inducing contraction of the repeats, (iii) and the knowledge from this research can be applied to other diverse simple repeat expansion diseases. As exemplified by the recent failed clinical trials for FXS from Novartis and Roche with their metabotropic glutamate receptor 5 (mGluR5) antagonists, most of the unsuccessful FXS studies were focused on the downstream pathway dysfunctions in FXS. Since FMRP modulates many different levels of pathways, FXS exhibits molecular, synaptic, and circuit levels of dysfunctions that cannot be easily corrected from the downstream. As my approach reactivates the *FMR1* by dealing with the upstream cause, the long CGG repeats, it has much greater potential to successfully cure the Fragile X Syndrome.

P-5: HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery

Jihye Park, Broad Institute

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with immunopathologies across the spectrum of infectious disease and autoimmunity. Here, we employ monoallelic immunopeptidomics to retrieve unique peptides presented by HLA-II heterodimers covering major alleles across diverse ancestries. We leveraged this expansive dataset and combined it with a curated dataset of HLA-II immunopeptidomes to develop computational models that predict peptide antigens based on HLA-II binding properties and structural features of the protein antigens from which these peptides derive. Combining both peptide and contextual protein features, we develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen
SARS-CoV-2. With CAPTAn, we look forward to identifying novel CD4+ T cell epitopes that were previously difficult to identify, as well as characterizing the T cell repertoire and TCR dynamics in disease. This future work will aid in deepening our understanding of adaptive immune responses.

P-6: Nanoparticles as Energy Transducers and Drug Delivery Carriers for Cancer treatment

Mikyung Kang, Massachusetts General Hospital at Harvard University

Cancer is one of the leading diseases that threaten human health worldwide. While there have been significant advances in cancer treatment over the years, many limitations still exist. One of the main challenges in treating cancer is the ability to selectively target cancerous cells without damaging surrounding healthy tissue. The use of light as an external stimulus for the precise spatiotemporal modulation of drug activity could offer a more targeted approach to drug therapy within the tumor. While the conventional methods of light-mediated treatment have shown promise, they are typically reliant on short-wavelength light (e.g., UV), which can lead to several unfavorable consequences, such as shallow tissue penetration and inevitable light scattering and absorption. A novel approach for phototherapeutic applications that utilizes near-infrared (NIR) light or X-rays has been proposed in recent years. NIR and X-rays exhibit the exceptional ability to penetrate through tissues and therefore have significant potential as an ideal energy source to activate PSs that have accumulated in deep tumor tissue.
Despite the numerous molecules proposed for clinical use that respond to near-infrared (NIR) light or X-rays, they are limited by complex synthesis procedures, low water solubility, and poor accumulation in targeted areas. These limitations greatly hinder their application in deep-tissue therapy. In order to utilize NIR or X-rays in conventional treatments, nanomaterials can be employed to transform the NIR or X-rays into UV/visible light. The nanoparticles that are designed not only to serve as carriers of various types of drugs but also to aid in the activation process by transferring energy from NIR or X-rays to UV-activable drugs loaded onto them may further offer promising chances for deeply located cancer treatment. The combination of light-mediated treatment and nanotechnology would offer a promising approach to overcoming current limitations in cancer treatment to fight against deep-seated tumors.

There are several challenges that must be addressed before light-mediated treatment can be widely used in clinical applications in the next decade. While some promising nanomaterials can convert NIR light or X-rays to short-wavelength light, the conversion efficiency is still insufficient. In addition, while many nanomaterials have shown significant therapeutic effects in preclinical studies, especially inorganic nanomaterials, their potential biosafety issues, such as non- biodegradability and long-term retention in the body, pose challenges. Despite these challenges, innovations in these research fields will likely lead to effective deep-tissue cancer treatment based on promising photo-mediated nanomedicine that can benefit human health in the future.

P-7: Direct therapeutic effect of sulfadoxine-pyrimethamine on nutritional deficiency induced enteric dysfunction in a human intestine chip

Seongmin Kim, Wyss Institute at Harvard University

Treatment of pregnant women in sub-Saharan Africa with sulfadoxine and pyrimethamine (SP) antimalarial therapy has been shown to reduce the incidence of lower birth weight infants. As many of these women experience malnutrition and enteric dysfunction, this observation raised the possibility that SP might have a direct effect on the ability of the pregnant women to absorb fats and nutrients from their diet that are required for fetal growth. To test this possibility directly, we leveraged an organ-on-a-chip model of the human intestine lined by young female patient-derived duodenal epithelial cells interfaced with intestinal microvascular endothelial cells (Intestine Chip). When cultured in nutrient deficient medium, the Intestine Chip replicates many features of enteric dysfunction, including loss of epithelial cells, villus blunting, decreased mucus production, suppressed nutrient absorption, and increased production of inflammatory cytokines. Treatment of the nutritionally deficient Intestine Chip with SP reversed all of these effects and displayed changes in transcriptomic and proteomic profiles consistent with significant enhancement of intestinal absorptive functions. Co-culture of complex human microbiota in these chips revealed that SP treatment also increases the proportion of gut microbiota, which has been previously associated with improved intestinal health. These data suggest that SP may indeed have direct beneficial effects on nutritional status in pregnant mothers with malnutrition and enteric dysfunction that could help to increase the birth weight of their children. Thus, SP should be explored as a potential treatment for this important global health problem, and the intestinal microbial environment and immune system should be more addressed in the future study because the intestine mediates an intricate interplay between the intestinal epithelial cells, microbiota, and the mucosal immune system during the infection and drug treatment.

P-8: Characterization of noncovalently associated human IgG heavy and light chains

Jeongin Son, Amgen at South San Francisco

Multiple quality-control checkpoints are necessary to monitor antibody integrity, especially immunoglobulin G (IgG), since the production of improperly folded or assembled antibodies would be detrimental to the immune response (Feige et al., 2010). Especially, the IgG heavy chains (HC) are kept in the ER and ultimately destroyed unless they combine with light chains (LC), in contrast to light chains, which may be secreted alone (Mains & Sibley, 1983). Once the HC CH1 domain is fully folded, the interaction of the folded LC and HC will be stabilized by the interchain disulfide link formed by ER-residing chaperones (Feige et al., 2010).

Previously, Hasegawa et al reported that the full-length human IgG clone was secretion- competent and spontaneously generated rod-shaped crystalline bodies (CBs) in stably transfected CHO cells. Moreover, only properly folded and secretion-competent mAbs can form CBs (Hasegawa et al., 2011). With this propensity of a CB-inducing mAb construct, in this study, we discovered a secretion-competent monoclonal human IgG-like molecule using a simple microscopic imaging-based screening strategy. We have found that the inter-disulfide bond mediated through cysteine in the CL domain and cysteine in the CH1 domain is dispensable for HC and LC secretion. Without an interchain disulfide bond, the assembled antibody's nave forms were identical with normal IgG. When these molecules ran through the analytical size exclusion chromatography (ASEC), the elution peaks of all IgG and IgG-like molecules were overwrapped. Furthermore, among the intrachain disulfide bond forming cysteine residues on LC that have been known to be important for LC's structural integrity, cysteine 134 in the CL domain has somewhat less impact on LC integrity but is important for disulfide-bond independent antibody folding and secretion. Also, IgG molecules and IgG-like molecules contain the target protein binding propensities. When we run the western blot with the target protein and each molecule, all the molecules showed binding propensities to the target protein. Through this study, we hypothesize that good enough Ab assembly for secretion does not require the covalently assembled LC and HC. The major inter-surface binding force between LC and HC is not yet elucidated. Also, this research can elucidate the importance of cysteines on LC for antibody assembly and secretion and suggest the useful scope of antibody modification in biopharmaceutical applications. As a further study, we want to render 3D modeling with MOE or Rosetta to analyze inter-surface binding forces such as hydrophobic interaction, hydrogen bonding, acid patching, charge patching, etc. Also, to understand the physiological effect of interchain disulfide bond formation and cysteine residue deletion on LC, we want to perform antibody production kinetics and binding assays through time-course product measurement and the Octet™ binding assay. Through

these assays, we expect that this study will allow us to understand the deep understanding of LC and HC assembly during mAb production and shed new light on the production of heavy-chain-only antibodies (HCAb).

P-10: Modulating IL-1β and its receptors shapes spike-specific CD4$^+$ T cell responses to mRNA vaccination

Hong-Jai Park, Yale University

Augmenting and sustaining a durable immunity provided by COVID-19 mRNA vaccines is important. Thus, we characterized S protein-specific CD4$^+$ T cells in healthy individuals who received COVID-19 mRNA vaccines utilizing single cell RNA-seq and mass cytometry followed by furthering such findings in animals. In humans, S protein-specific CD4$^+$ T cells highly expressed IL-1 receptor (R) 1 and its decoy receptor IL-1R2. IL-1β promoted IFN-γ expression by S protein- stimulated CD4$^+$ T cells, which was furthered by adding anti-IL-1R2-blocking antibodies, supporting the functional implications of IL-1R1 and IL-1R2. Following the 2nd dose of vaccination, IL-1R1 expression increased while IL-1R2 expression decreased in S protein-specific CD4$^+$ T cells. The expression levels of such cytokine receptors correlated with S-specific antibody production. Also, IL-1R1 neutralization suppressed IFN-γ production by S-protein specific CD4$^+$ T cells in mice immunized with COVID-19 mRNA vaccine. Our findings provide novel insight into the role of IL-1β and its receptor system in developing COVID-19 mRNA vaccine-induced CD4$^+$ T cell immunity. Lastly, the association of IL-1β and its receptors with the development of S-specific humoral immunity will be investigated in patients with immune disorders (CVID or SLE) before and after mRNA vaccination.

P-11: PHD3 senses and controls metabolism in adipocytes

Ji-Seul Han, Harvard Medical School

Sensing energy status is important to control the balance between storage and consumption of energy source. An imbalance toward energy storage can lead to obesity and metabolic diseases. PHD3 (Prolyl Hydroxylase Domain 3) is an enzyme that hydroxylases substrate proteins to control their activity and stability. In addition to its well-known functions in the degradation of HIFα (Hypoxia- inducible Factor α), PHD3 also plays a critical role in the regulation of lipid metabolism by sensing metabolites. Upon energy surplus, PHD3 promotes hydroxylation of ACC2 (Acetyl CoA Carboxylase 2), resulting in the suppression of fatty acid oxidation in skeletal muscle. Although adipose tissue is crucial metabolic organ for energy homeostasis via regulating lipid metabolism, it is still elusive whether PHD3 regulate metabolism in adipose tissue. In this study, we found that PHD3 KO mice is resistant to diet-induced obesity with reduced fat mass upon high-fat diet feeding. Metabolomic analyses revealed that PHD3 is a novel regulator of amino acid metabolism, with adipose PHD3 determining cellular glutamate levels in obesity. Our findings suggest that PHD3 loss accelerates cellular metabolism in adipocytes, leading to an increase in energy expenditure and alteration of amino acid levels. These results imply that PHD3 could be a potential therapeutic target for obesity and related metabolic diseases.

P-12: Delivery of costimulatory blockade to lymph nodes promotes transplant acceptance in mice

Sungwook Jung, Brigham Women's Hospital at Harvard University

The lymph node (LN) is the primary site of alloimmunity activation and regulation during transplantation. Here, we investigated how fibroblastic reticular cells (FRCs) facilitate the tolerance induced by anti-CD40L in a murine model of heart transplantation. We found that both the absence of LNs and FRC depletion abrogated the effect of anti-CD40L in prolonging murine heart allograft survival. Depletion of FRCs impaired homing of T cells across the high endothelial venules (HEVs) and promoted formation of alloreactive T cells in the LNs in heart-transplanted mice treated with anti-CD40L. Single-cell RNA sequencing of the LNs showed that anti-CD40L promotes a Madcam1$^+$ FRC subset. FRCs also promoted the formation of regulatory T cells (Tregs) in vitro. Nanoparticles (NPs) containing anti-CD40L were selectively delivered to the LNs by coating them with MECA-79, which binds to peripheral node addressin (PNAd) glycoproteins expressed exclusively by HEVs. Treatment with these MECA-79–anti-CD40L-NPs markedly delayed the onset of heart allograft rejection and increased the presence of Tregs. Finally, combined MECA-79–anti-CD40L-NPs and rapamycin treatment resulted in markedly longer allograft survival than soluble anti-CD40L and rapamycin. These data demonstrate that FRCs are critical to facilitating costimulatory blockade. LN-targeted nanodelivery of anti-CD40L could effectively promote heart allograft acceptance. Future studies to query the transcriptomes of FRC subclasses under costimulatory blockade at various stages after transplantation would increase our understanding of how these therapeutics change the milieu of the LN. Examining the Madcam1$^+$ cells

in the spleen and the cells that drive immune regulation in both LNs and spleen are also important future endeavors.

P-13: A New Horizon for New Drug Development based on Protein Structure, Pharmaco-Net

Young Bin Park, Calici Therapeutics Inc.

Pharmaco-Net is an innovative web application designed to revolutionize the process of discovering functional materials in new drug and food-tech industries. By leveraging cutting-edge technologies such as protein 3D structure analysis, small molecule identification, artificial intelligence (AI), and in-silico docking, Pharmaco-Net offers a powerful platform for accelerating the development of novel therapeutics and food-related products. One of the core features of Pharmaco-Net is its ability to analyze the intricate 3D structures of proteins. Understanding the structure-function relationships of proteins is crucial in identifying potential drug targets and optimizing their interactions with small molecules. With advanced algorithms and computational tools, Pharmaco-Net enables researchers to explore the structure of proteins in detail, unraveling their functional properties and identifying key binding sites. Moreover, Pharmaco-Net integrates AI algorithms to enhance the drug and food-tech discovery process. The AI capabilities assist in analyzing large datasets, predicting molecular interactions, and identifying potential lead compounds. By leveraging machine learning and data-driven approaches, Pharmaco-Net empowers researchers to make informed decisions, reducing the time and cost associated with traditional trial-and-error methods. In addition, the web application incorporates in-silico docking techniques, allowing researchers to simulate the binding of small molecules to target proteins. This virtual screening process helps identify potential drug candidates or functional food components with high binding affinity and therapeutic potential. By employing computational modeling and simulations, Pharmaco-Net expedites the initial stages of drug discovery and food-tech development, providing valuable insights before experimental validation. Overall, Pharmaco-Net is a powerful and comprehensive web application that combines protein 3D structure analysis, small molecule identification, AI algorithms, and in-silico docking. By leveraging these tools, researchers and scientists can accelerate the discovery of functional materials, enabling the development of new drugs and innovative food-tech products with improved efficiency and reduced costs.

P-14: Development of Precision Medicine for Patients with Atopic Dermatitis

Joonsung Hwang, CUePEAK BIO. Co. ,Ltd.

Atopic dermatitis (AD) is a chronic inflammatory skin disease results in itch skin, but add on its painful cracking, swollen, and bleeding of the skin. Typically starts in childhood, with changing severity over the years. Many patients develop asthma or allergic diseases, called as Atopic March. More than 150 million people in the world suffer from this disease. In Korea alone, there are more than 1 million patients, and unfortunately, about 30% of them are under 4 years old. Not only high incidence, there are limitations of both diagnosis and therapeutics. Doctors diagnose diseases only through examinations and questionnaires. It is difficult to say that this is Scientific examination. In case of therapeutics, there is no suitable treatment for children under 2 years old who have the most patients. Also, the same treatment is applied to all patients regardless of etiology. Here is the important challenge to be must-solved. It is need that the customized medicine based on each patient's etiology and therapeutics applicable to all patients including infants and toddlers.

Filaggrin (FLG) is a major epidermal protein expressed in the stratum corneum, which is the upper most layer of the skin, and is essential for the skin barrier function. Its genetic mutations are major predisposing factors for AD. When an abnormality occurs in these Filaggrin genes, the expression of Filaggrin protein is decreased and then the skin barrier function is lost. Antigen easily penetrated into the skin barrier, and Atopic Dermatitis develops. In particular, it has been reported that patients with Filaggrin abnormality increase the severity and persistence of atopic dermatitis and also increase the risk of asthma and allergic diseases. As such, special care is required for atopic patients with filaggrin abnormality. We have 3 products that we have patented technology to accurately detect atopic dermatitis. If FLG abnormalities is detected, CP001 ointment is prescribed as diagnosis-based therapeutics as our 2nd product. If not, CP002 drug is prescribed as an anti-inflammatory drug. It cures the cause of the disease, depending on etiology of disease, and not just the inflammation of the skin. Our products enable us to diagnose atopic dermatitis accurately by determining the cause of disease and prescribe customized medicine.

P-15: Novel Long-Acting Microsphere by InnoLAMP Technology

Heeyong Lee, G2GBIO, Inc

InnoLAMP is an innovative long-acting microsphere production technology that effectively addresses critical unmet needs encountered in conventional technologies, including high manufacturing costs due to low yield and injection site reactions. InnoLAMP uses an efficient solvent removal method (patent: KR10-2047983) and allows mass production of homogeneous microspheres and the development of microspheres with higher drug loading, leading to improved yields with lower manufacturing costs. Further, InnoLAMP advances bioavailability and increases drug loading which reduces microsphere quantities required for injections and InnoLAMP itself exhibits properties that minimize the inflammation occurrence and enhanced anti-inflammatory effects, leading to a decrease in injection site reactions. InnoLAMP successfully encapsulates diverse active pharmaceutical ingredients (APIs), including small molecules and peptides. GB-5001 is a monthly donepezil-loaded microsphere injectable targeting Alzheimer's disease. Phase 1 clinical trial is ongoing (NCT05525780), evaluating low-, intermediate-, and high-doses of GB-5001, comparing its performance with Aricept® 10 mg. Human pharmacokinetic data from the low- and medium-dose cohorts are obtained, satisfying the desired profile for a monthly donepezil injectable with no safety concerns. The results demonstrate promising potential for drug approval through bioequivalence testing using steady-state conditions of GB-5001 and Aricept® 10 mg. Another example is GB-7001, a semaglutide-loaded microsphere injectable targeting type 2 diabetes and obesity, with administration frequencies of one month and two to three months. In conclusion, InnoLAMP is a technology showcasing the remarkable potential for revolutionizing the field of microspheres, establishing new standards for cost-efficiency and reducing injection site reactions, and is capable of encapsulating various APIs for diverse indications.

P-16: Design of Experiments (DOE) for Optimization of the Cell Culture Process

Michael J. Kim, Prestige Biologics Co. Ltd.

Design of Experiments (DOE) is a systematic and efficient statistical method that enables studying the relationship between multiple input variables and output variables. Prestige Biologics has used DOE in many stages of Drug Substance development and successfully contributes to client's success. In this poster, Prestige Biologics demonstrates how Prestige Biologics utilizes DOE in optimizing processes and improving titer through media screening.

P-17: WIREGENE Nerve Conduits for Spinal Cord and Peripheral Nerve Regeneration

Jung Keun Hyun, WIREGENE Co.Ltd

Wiregene is a leading company specializing in the development of innovative solutions for regenerating damaged peripheral and central nervous systems. Our nerve conduits, designed for peripheral nerve and spinal cord regeneration, are unique products approved by the FDA, featuring biodegradable and biocompatible materials. These conduits possess finely aligned microchannels, each with a diameter of less than 25µm, and over 5,000 microchannels are present within a single conduit. Numerous nanopores are also integrated within each microchannel, confirming the structural alignment through rigorous testing methods. In a groundbreaking study on human-sized minipigs, our conduits were implanted into transected sciatic nerves, resulting in the profound recovery of denervated muscles within 16 weeks. The recovered muscles exhibited weight and diameter equal to or higher than those treated with autografts. Similarly, when our conduits were implanted into completely transected spinal cords, significant functional recovery was observed within 12 weeks, enabling movement recovery in hindlimbs and tails. We have the capability to further enhance neuronal regeneration by combining Schwann cells or sustained-release delivery systems with regeneration-associated factors. This synergistic approach holds immense potential for improving outcomes in individuals with neuronal damage. Wiregene's achievements in nerve regeneration demonstrate our commitment to advancing the field. Through cutting-edge technology, rigorous scientific investigation, and strategic collaborations, we aim to revolutionize the treatment of neuronal damage. Our research holds promise for patients, healthcare providers, and the scientific community, ushering in a new era of functional restoration and improved quality of life for those affected by peripheral nerve and spinal cord injuries.

P-18: Evaluation of *In chemico* Skin Sensitisation: Direct Peptide Reactivity Assay

Dong-Won Son, Biotoxtech

Skin sensitizers are chemical substances that can elicit allergic responses or diseases in the skin upon contact. To assess the skin sensitizing potential of the test substance, animal tests such as guinea-pig maximization test, and local lymph node assay (LLNA) are performed. However, as interest in animal welfare increases, test methods that replace animal experiments have recently been developed and applied. *In chemico* skin sensitisation: Direct Peptide Reactivity Assay [DPRA, OECD Test Guideline 442C] is composed of applying a test substance on synthetic peptides containing cysteine or lysine and determining the skin sensitization measured by reactivity of the test substance. In this study, the skin sensitization of the proficiency substance presented in OECD TG 442C was evaluated. As a result, 2,4-Dinitrochlorobenzene (DNCB), Oxazolone, Benzylideneacetone, 2,3-Butanedione and 4'-Methoxyacetophenone were determined to be positive, and Farnesal, 1-Butanol, 6-Methylcoumarin and Lactic acid were determined to be negative, and it was confirmed that all of them occurred within the results and ranges presented in the OECD Test guideline. Through this study, it was confirmed that the DPRA test method can be applied as a test method for predicting skin sensitizing chemicals and is suitable for evaluating skin sensitization in the GLP environment.

Past Awardees

KASBP-DAEWOONG ACHIEVEMENT

2009	Jong Eun Kim	Gilead Sciences, Inc., Currently Kainos Medicine Inc, Korea
2010	David C. Chu	University of Georgia
2011	Sung Ho Kim	University of California, Berkeley
2012	Dennis Choi	Stony Brook Medicine and Stony Brook University
2013	Joseph Kim	Inovio Pharmaceuticals
2014	Kinam Park	Purdue University
2015	Jong Sung Koh	Genosco
2016	Jang-Ho Cha	Novartis
2017	Peter Park	Bicycle Therapeutics
2018	Jong Wook Lee	Daewoong Pharmaceuticals
2019	Kwang-Soo Kim	Harvard Medical School
2020	Larry Kwak	City of Hope
2021	Young-Whan Park	National OncoVenture
2022	Jae Park	Memorial Sloan Kettering Cancer Center (MSKCC)

KASBP RECOGNITION AWARD

2015	Jong Wook Lee	Daewoong Pharmaceutical Co. Ltd.

KASBP-DAEWOONG FELLOWSHIP

2006	JaeKi Min (New York University), Hahn Kim (Princeton University), HyeJin Park (Rutgers University)
2007	JiSook Moon (Harvard University), SungYeon Park (Rutgers University), SeokGeun Lee (Columbia University)
2008	HeungKyu Lee (Yale University), JungHwan Kim (Rutgers University), MinSik Kang (Columbia University)
2009	JinAh Park (Harvard University), JaeMin Choi (Yale University), DeokHo Kim (Johns Hopkins University)
2010	JungMin Kee (Rockefeller University), HyungWook kim (NIH), SeJin Ahn (Harvard University)
2011	MooRi Han (University of California, LA), HwanJong Jang (Boston College)
2012	JeongHo Jang (Columbia University), JaeWoo Choi (Oregon State University)
2013	JangEun Lee (University of Pennsylvania), Eun Chan Park (Rutgers University)
2014	Kimberly H. Kim (Harvard University), Seung Koo Lee (Weill Cornell Medical College), Min-Sik Kim (Johns Hopkins University)
2015	Jiyeon Kim (UT Southwestern), Sun Mi Park (Memorial Sloan-Kettering Center), Byeong Seon Kim (University of Pennsylvania)
2016	Sang Bae Lee (Columbia University), Junil Kim (University of Pennsylvania), Ho-Keun Kwon (Harvard Medical School)
2017	KyeongJin Kim (Columbia University Medical Center), Min-Ji Bak (Ernest Mario School of Pharmacy), Heung Sik Hahm (Free University Berlin)
2018	Jung Ho Hyun (Max-Plank Florida Institute for Neuroscience), Seung Hoon Lee (Harvard Medical School), Jang Hwan Cho (Boston University)
2019	Hyunyong Koh (Boston children's Hospital), Young Cha (MeLean Hospital), Hojong Yoon (Harvard University)
2020	Jun Young Hong (Yale University), Heeseon An (Harvard Medical School), Yoon Seok Kim (Stanford University)
2021	Youngeun Kim (Harvard Medical School), Juhyun (Julie) Oh (Harvard Medical School), Rafael Taeho Han (University of California, San Francisco)

2022	Inyoung Jung (Univ. of Pennsylvania), Lee Joon Kim (Lawrence Berkeley National Laboratory), Benjamin Lew (UIUC)

KASBP-GREEN CROSS (CURRENTLY, KASBP-GC BIOPHARMA) FELLOWSHIP

2011	HanSang Cho (Harvard Medical School), SungWoong Kang (Johns Hopkins University), MiYeon Kim (Columbia University), JaeYoung Soh (Rutgers University), SungYong Hwang (NIEHS/NIH)
2012	WonJin Cho (Drexel University), HyoJung Kang (Yale University), JungHyun Lee (Columbia University), YongJae Lee (Yale University), JaeHyun Yoon (NIH)
2013	Yunjong Lee (Johns Hopkins University), Jun-Dae Kim (Yale University), Bae-Hoon Kim (Yale University), Ja Young Kim-Muller (Columbia University)
2014	Catherine Rhee (University of Texas at Austin), Ji-Seon Seo (The Rockefeller University), Sehyun Kim (New York University)
2015	Young-Su Yi (New York University), Hee-Woong Lim (University of Pennsylvania), Bloria Bora Kim (The Pennsylvania State University)
2016	Eui Tae Kim (University of Pennsylvania), Kihyun Lee (Weill Cornell Medical Science)
2017	Seung-Yeol Park (Harvard medical school), Young Bok Abraham Kang (Harvard medical school)
2018	Jae Yeon Hwang (Yale University), Youngjin Kim (Rockefeller University)
2020	Namgyu Lee (University of Massachusetts)
2022	Thomas TaeHyung Kim (Picower Institute, MIT), Jaehyeok Jin (Columbia Univ.), Seung Hun Park (MGH, Harvard Medical School)

KASBP-HANMI FELLOWSHIP

2011	HyungJin Ahn (Rockefeller University), ChangHoon Cho (Abramson Research Center)
2012	YuNa Kim (University of North Carolina), HyunSeob Tae (Yale University), InHye Lee (NIH)
2013	JooHee Lee (Memorial Sloan-Kettering Cancer Center), KyungRyun Lee (Rutgers University), ManRyul Lee (Indiana University)
2014	Young Chan Cha (Wistar Institute), Min-Kyu Cho (New York University), Lark Kyun Kim, (Yale University), Yu Shin Kim (Johns Hopkins University)
2015	Seonil Kim (New York University), Peter B. Kim (Yale University)
2016	Sungwhan Oh (Harvard Medical School), Won-Gil Lee (Yale University), Hee-Jin Jeong (Harvard Medical School)
2017	Seungkyu Lee (Harvard Medical School), Soo Seok Hwang (Yale University), Heeoon Han (University of Pennsylvania)
2018	Jae Yeon Hwang (Yale University), Yeong Shin Yim (MIT), Dahea Yu (Rutgers University)
2021	Taekyung Kwak (The Wistar Institute), WooriKim (Harvard Medical School), Tae-Yoon Park (McLean Hospital)
2022	Taekyung Kwak (The Wistar Institute), WooriKim (Harvard Medical School), Tae-Yoon Park (McLean Hospital)

KASBP-LG CHEM FELLOWSHIP

2017	Kyoung-Dong Kim (Wistar Institute), Seok-Man Ho (Icahn School of Medicine at Mount Sinai)
2019	Jea Hyun Baek (Biogen Inc.), Donggi Paik (Harvard Medical School)

KASBP-QURIENT FELLOWSHIP

2018	Soeun Kang (University of Illinois at Chicago), Do Hyung Kim (Johns Hopkins University)

KASBP-YUHAN FELLOWSHIP

2011	Kiyoung Kim (Boston University), Joongseop Shim (Johns Hopkins University)
2012	Yemin Huh (University of Michigan), Sookhee Bang (University of Pennsylvania), Jungho Baik (Columbia

University)

2013	Dong Jun Lee (University of Chicago), Ingyu Kim (Yale University), Ja Yil Lee (Columbia University)
2014	Seouk Joon Kwon (Rensselaer Polytech Institute), Jeongmin Song (Yale University), Jae-Hyun Yang (Harvard Medical School), Wan Seok Yang (Columbia University)
2015	Min-Joon Han (Harvard Medical School), Minjung Kang (Cornell University)
2016	Ki Su Kim (Harvard Medical School), Hongjae Sunwoo (Harvard Medical School), Seo-Young Park (University of Massachusetts)
2017	Hanseul Yang (Rockefeller University), Ji-Hoon Park (NIH), Hong-Yeoul Ryu (Yale University)
2018	Sangdoo Kim (Harvard Medical School), Baehyun Shin (Harvard Medical School), Mikyung Yu (Harvard Medical School)
2021	Sekyu Choi (Harvard University), Sungyun Cho (Weill Cornell Medical Colleage), Dongheon Lee (Duke University)
2022	Yongmin Cho (Harvard Medical School), Ho Namkung (Johns Hopkins University), Hyeonglim Seo (UCSD)

KASBP-DONG-A FELLOWSHIP

2009	SangHo Choi (NIH)
2010	Min Jae Lee (Yale University)

KASBP FELLOWSHIP

2016	Jung-Eun Jang (New York University), Byungsu Kwon (MIT)
2010	SangRyung Kim (Columbia University), TaeSook Yoon (Rutgers University), EunMi Huh (Cal. Tech.)
2015	Mi Jung Kim (Duke University), Minyoung Park (The Rockefeller University)
2019	Kyusik Kim (University of Massachusetts Medical School)

KASBP-KSEA FELLOWSHIP

2013	Sung In Lim (University of Virginia)
2014	Keun-woo Jin (Temple University)

KASBP-KUSCO FELLOWSHIP

2008	HyunHo Kim (National Institutes of Health), TaekBeom Ohn (Harvard Medical School), WonAh Joo (Wistar Institute)

KASBP-KRICT FELLOWSHIP

2009	SeungSik Shin (Rutgers University), EunJoo Jeong (Columbia University), KyuWon Baek (University of Pennsylvania)

KASBP-SAMSUNG FELLOWSHIP

2019	Eunju Im (Nathan S. Lline Institutue for Psychiatry Research), Jongho Park (Massachusetts General Hospital)

KASBP-KRIBB FELLOWSHIP

2019	Song Min (Harvard Medical School), Eun-Ik Koh (University of Massachusetts Medical School)

KASBP-KHIDI FELLOWSHIP

2010	JaeHyunBae (Yale University), HeeYeon Cho (Boston College)

2020 Haejin Yoon (Harvard Medical School)

2022 Se-Yeong Oh (Emory University), Soojin Lee (UMass Medical School)

KASBP- CHOONGCHEONGBUK-DO FELLOWSHIP

2020 Su Bin Lim (Johns Hopkins University), Brandon Suh (Harvard University)

KASBP-ISUABXIS FELLOWSHIP

2020 Jongwoo Son (University of Wisconsin-Madison), Won Dong Lee (Princeton University)

2021 Yong-Woo Jun (University of Massachusetts Medical School), Yu Young Jeong (Rutgers University)

KASBP-SEEGENE FELLOWSHIP

2020 Haejin Kim (Columbia University)

KASBP-MDIMUNE FELLOWSHIP

2020 Young Jae Woo (Icahn School of Medicine at Mount Sinai)

KASBP-NANOENTEK FELLOWSHIP

2020 Jongkyun Kang (Brigham and Women's Hospital)

KASBP-ENZYCHEM FELLOWSHIP

2021 Jinwoo Kim (Stony Brook University)

KASBP-SAMYANG FELLOWSHIP

2021 Kyongman An (Johns Hopkins University)

KASBP-SK BIOPHARM FELLOWSHIP

2021 Sung-Hee Yoon (Harvard Medical School)

KASBP-SK BIOSCIENCE FELLOWSHIP

2022 Woo Yong Park (NCI), Sungwook Jung (BWM at Harvard), Yunju Jeong (BWH at Harvard)

KASBP-ABTIS FELLOWSHIP

2021 Yunju Yang (University of Texas Health Science Center at Huston)

KASBP-EUTILEX FELLOWSHIP

2021 Yun Hwa Choi (University of Wisconsin-Madison)

KASBP-KPBMA FELLOWSHIP

2021 Dahye Kang (Harvard Medical School), Bumjun Kim (Princeton University)

KASBP-ITP/YONSEI FELLOWSHIP

2021 Jaeho Shin (University of Notre Dame), Jeonghwan Kim (OSU & OHSU)

2022 Jae Kyo Yi (DFCI at Harvard Medical Center)

KASBP-KAIST/GCC FELLOWSHIP

2021 Seungbeom Ko (Medical University of South Carolina), Annie J. Lee (Columbia University Medical Center)

2022 Hyejoon Jeong (Univ. of Pennsylvania)

KASBP-DAEWOONG SCHOLARSHIP

2006	Jin K. Pai (Handok Pharmaceuticals, Korea)
2007	YoungWhan Park (National Cancer Center, Korea)
2008	Young-Choon Moon (PTC Therapeutics)
2009	HongYong Kim (Novartis)

MOGAM-KASBP SCHOLARSHIP

2022	Yehlin Cho (MIT), Jayoung Ryu (Harvard), Jee Won Yang (Caltech), Hyoann Choi (Georgia Tech), Sookyung Kim (UMass Medical School), HyeRin Leah Yim (Mount Sinai), Byunggik Jason Kim (Johns Hopkins), Sally Chung (Johns Hopkins)

2023 KASBP Spring Symposium Attendees

	Last name	First name	한글	Affiliation	Area	Choose a group
1.	Abbink	Peter		Batavia Biosciences	MA	Cell and Gene Therapy / Rare Diseases
2.	BAE	EUNAH	배은아	Takeda	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
3.	Bae	Jihyun	배지현	University of Florida	FL	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
4.	Baek	Juhyun	백주현	That's Nice	NY	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
5.	Byun	JungHoon	변정훈	KHIDI	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
6.	CHA	SANG HOON	차상훈	Aprilbio	KOREA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
7.	Chang	Chan Il	장찬일	Atinum Investment	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
8.	Chang	Hemmie	장혜 미	Foley Hoag	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
9.	Chang	Kern	장건희	Janssen R&D	PA	CMC / Quality Assurance / Regulatory Affairs / Project Management
10.	Chang	Yeonji	장연지	Whitehead Institution	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
11.	Cho	Min-Kyu	조민규	Novartis	MA	CMC / Quality Assurance / Regulatory Affairs / Project Management
12.	Cho	Sang Kyu		Analysis Group	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
13.	Cho	Yong	조용성	YC Consulting	CA	CMC / Quality Assurance / Regulatory Affairs / Project Management
14.	Choe	Yun H.	최윤	ArentFox Schiff LLP	NJ	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
15.	Choi	Alan	최성구	Ildong Pharmaceutical Co.	KOREA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
16.	Choi	Bong Geun	최봉근	WIREGENE CO., Ltd.	KOREA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
17.	Choi	Dayun	최다윤	MCPHS University	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
18.	Choi	Doo Eun	최두은	Massachusetts General Hospital	MA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
19.	Choi	Hailey	최지혜	MCPHS	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
20.	Choi	Hee June	최희준	Merck	MA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
21.	CHOI	HYE KYUNG	최혜경	VSPharmTech	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
22.	Choi	Jay	최재명	Huons USA, Inc.	CA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
23.	Choi	Jeonghoon	최정훈	Wave Life Sciences	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
24.	Choi	Jinkuk	최진국	Biogen	MA	Cell and Gene Therapy / Rare Diseases
25.	Choi	Jonggil	최종길	SK Life Science	NJ	Cell and Gene Therapy / Rare Diseases
26.	Choi	Jung-Hwan	최정환	New York University	NY	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
27.	Choi	Soon Gang	최순강	Ginkgo Bioworks	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations

	Last name	First name	한글	Affiliation	Area	Choose a group
28.	Choi	Sun	최선아	University of Illinois at Chicago College of Pharmacy	IL	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
29.	Choi	Sung Hugh	최성휴	Pinetree Therapeutics	MA	CMC / Quality Assurance / Regulatory Affairs / Project Management
30.	Choo	Min-Kyung	추민경	Ingenia Therapeutics	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
31.	Chun	Sejong		Novartis	MA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
32.	Chung	Alex	정관호	Perkins Coie LLP	DC	Cell and Gene Therapy / Rare Diseases
33.	Chung	HaeWon	정해원	Asimov	MA	Cell and Gene Therapy / Rare Diseases
34.	Chung	Hye Kyung	정혜경	Rapigen America Inc	MD	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
35.	Chung	Seung Wook	정승욱	Janssen R&D	PA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
36.	Chung	SeungSoo	정승수	BnH Research	KOREA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
37.	Chung	Seungwon	정승원	AbbVie	IL	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
38.	Chung	Yoojin	정유진	Decibel Therapeutics	MA	Cell and Gene Therapy / Rare Diseases
39.	Chung	Younghoon	정영훈	MCPHS	MA	CMC / Quality Assurance / Regulatory Affairs / Project Management
40.	Eom	Jonathan	엄준식	Brandeis University	MA	Infectious Diseases / Vaccines / RNA Therapeutics
41.	Eom	Taesun	엄태선	Beam Therapeutics	MA	Infectious Diseases / Vaccines / RNA Therapeutics
42.	Eum	Hyunae	음현애	Huons	KOREA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
43.	Ha	Dae Gon		Stifel Financial	MA	Cell and Gene Therapy / Rare Diseases
44.	Ha	Junho	하준호	Initium therapeutics	MA	Cell and Gene Therapy / Rare Diseases
45.	Hahm	Kyung Soo	함경수	BL Corp.	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
46.	Han	Daehee	한대희	Standigm	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
47.	Han	Ji Seul	한지슬	HARVARD MEDICAL SCHOOL	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
48.	Han	Mijin	한미진	Biotoxtech	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
49.	Han	Sangyeul	한상열	Ingenia Therapeutics	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
50.	Han	Wooseok	Wooseok Han	Cyrus Therapeutics	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
51.	Heo	Seok	허석	Eli Lilly and Company	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
52.	Holm	Karsten		Medicilon	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
53.	Hong	Jaesang	홍재상	Massachusetts General Hospital	MA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
54.	Hong	Miyoun		Seoul	KOREA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
55.	Hong	Ted	홍찬영	AstraZeneca	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
56.	HWANG	JOONSUNG	황준성	CUePEAK BIO. Co.,Ltd.	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
57.	Hwang	Seungyong	황승용	GRAIL	CA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
58.	Hwang	Soyoung	황소영	Genosco	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
59.	Hwang	Sungyong	황성용		MD	Clinical Trial & Development / Clinical Pharmacology / Biostatistics

	Last name	First name	한글	Affiliation	Area	Choose a group
60.	Hyun	Byung Hwa	현병화	KAIST	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
61.	Hyun	Jung Keun	현정근	Attnem Inc. / Wiregene Co., Ltd.	KOREA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
62.	Im	Eunju	임은주	Amyloid Solution Inc.	NJ	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
63.	Im	Wonpil		Lehigh University	PA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
64.	JANG	HYUNSUN	장현순	Dt& Investment	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
65.	Jang	Miran	장미란	Celltrion	NY	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
66.	Jee	Sang Eun	지상은	Xtalpi Inc.	MO	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
67.	Jeon	Youngha	전영하	University of rhode island	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
68.	Jeong	Euijoon	정의준	Ring Therapeutics	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
69.	Jeong	Sean	Seungwon	Hanall Biopharma	MD	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
70.	Jeong	Sinyoung	정신영	Intek Scientific Inc	MA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
71.	Jeong	Yu Young	정유영	Rutgers University	NJ	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
72.	Jin	Joon	진준영	Hanwha Impact	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
73.	Jo	Hakryul	조 학렬	Kymera Therapeutics	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
74.	Jo	Hansang		Absology Co., Ltd.	KOREA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
75.	Jo	Hyunsun	조현선	Pin Therapeutics	CA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
76.	Jo	Seunghee	조승희	Blueprint Medicines	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
77.	Jo	Sujin	조수진	Hana Ventures	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
78.	Joo	HyungKweon	주형권	H Linkers USA	NY	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
79.	Joo	Seunghoon	주승훈	Tenafly high school	NJ	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
80.	Jung	Da-Jung	정다정	Brigham and Women's Hospital	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
81.	Jung	Hailey	정회량	Roche	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
82.	Jung	HooYoung	정후영	BnH Research	KOREA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
83.	Jung	Hosun	정호선	CRISPRTx	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
84.	Jung	Hyun Jin	정현진	Columbia	CA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
85.	Jung	Hyunkyung	정현경	Medic Life Sciences	CA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
86.	Jung	Jaeyong	정재용	Rutgers University	NJ	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
87.	Jung	Sangwon	정상원	MVRIX	KOREA	Infectious Diseases / Vaccines / RNA Therapeutics

	Last name	First name	한글	Affiliation	Area	Choose a group
88.	Jung	Suk		Korea University	KOREA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
89.	Jung	Sungwook	정성욱	Harvard Medical School	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
90.	Jung	Young Chun	정영춘	Mersana Therapeutics Inc.	MA	CMC / Quality Assurance / Regulatory Affairs / Project Management
91.	Kam	Yoonseok		Agilent Technologies	MA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
92.	KANG	BYUNGHAK	강병학	Novartis	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
93.	Kang	Jongkyun	강종균	Harvard Medical School/BWH	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
94.	Kang	Junghyun		MCPHS	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
95.	KANG	KIHWA	강기화	NIH	MA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
96.	Kang	Mikyung	강미경	Mass General Hospital	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
97.	Kang	Min-Suk	강민석	Columbia University Medical Center	NY	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
98.	Kang	Pilsoo	강필수	Sanofi	MA	Cell and Gene Therapy / Rare Diseases
99.	Kang	Sanggoo	강상구	MedySapiens, Inc.	KOREA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
100.	Kang	Soo Im	강수임	Columbia University Irving Medical Center	NY	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
101.	kim	Byungchan	김병찬	Xtalpi Inc	NJ	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
102.	Kim	Changgun	김창근	GNT Pharma	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
103.	Kim	Dae-Shik	김대식	Eisai Inc	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
104.	Kim	Dayoung		Hankuk University of Foreign Studies	KOREA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
105.	Kim	Dong-Hyun	김동현	Yuhan Corporation	OTHER	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
106.	Kim	Dongkyoon	김 동균	Initium Therapeutics	CA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
107.	Kim	Dongsung	김동성	MSKCC	NY	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
108.	Kim	Elaine		AbbVie Inc.	IL	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
109.	Kim	Grace	김은경	AbbVie Inc.	IL	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
110.	Kim	Hyelim		PineTree Therapeutics	MA	CMC / Quality Assurance / Regulatory Affairs / Project Management
111.	Kim	Hyo Jeong		Boston Children's Hospital	MA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
112.	Kim	Hyoujin	김효진	MIT	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
113.	Kim	Jae-Hun	김재훈	OliPass	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
114.	Kim	Jinah		KHIDI USA	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
115.	Kim	Jinsan	김진산	Curable Co. Ltd.	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations

	Last name	First name	한글	Affiliation	Area	Choose a group
116.	KIM	JU HO	김주호	BIO POLICY DIVISON, CHUNGCHEONGBUK-DO	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
117.	Kim	Jun Yong	김준용	Harvard medical school	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
118.	KIM	JUNGHWAN	김정환	ILLIMIS THERAPEUTICS	KOREA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
119.	Kim	Kyung	김경효	AbbVie	IL	Bioinformatics / A.I. / Machine Learning / Quantitative Science
120.	Kim	Kyungsu	김경수	Massachusetts General Hospital and Harvard Medical School	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
121.	Kim	Kyusik	김규식	Tessera Therapeutics	MA	Cell and Gene Therapy / Rare Diseases
122.	Kim	Lauren	김지은	AbbVie	IL	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
123.	Kim	Michael J	김마이클	Prestige BioPharma Group	KOREA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
124.	Kim	Minji	김민지	Cross Border Partners, LLC	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
125.	Kim	Munkyung	김문경	Kaigene	MD	Immunology-Oncology / Autoimmune / Inflammatory Diseases
126.	KIM	MYUNGJIN	김명진	DT&Investment	KOREA	Digital Health / Digital Therapeutics
127.	Kim	Najung	김나정	Adjuvant Partners	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
128.	Kim	Nam Cheol	김남철	United States Pharmacopeia (USP)	MD	CMC / Quality Assurance / Regulatory Affairs / Project Management
129.	Kim	Sally	김지후	MGH	MA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
130.	Kim	Sang Gyun	김상균	InterVest	KOREA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
131.	KIM	SAURYANG	김소량	BIOTOXTECH CO.,LTD.	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
132.	Kim	Scott		Zymedi	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
133.	Kim	Sean	김무진	American Pharmacists Association	DC	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
134.	Kim	Sehyun		Merck	NJ	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
135.	Kim	Seonghan	김성한	Lehigh University	PA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
136.	Kim	Seongjin	김성진	Cyrus Therapeutics Inc.	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
137.	Kim	Seongjun		MCPHS University	MA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
138.	Kim	Seongmin		Harvard University	MA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
139.	Kim	Seyoon (Scott)	김세윤	Samyang Holdings Corporation	KOREA	Cell and Gene Therapy / Rare Diseases
140.	Kim	Stephen		Qiagen	MD	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
141.	Kim	Sun	김선영	Ildong Pharmaceutical	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations

	Last name	First name	한글	Affiliation	Area	Choose a group
142.	Kim	Sung ki	김성기	Massachusetts Biomed Lab, Inc.	MA	CMC / Quality Assurance / Regulatory Affairs / Project Management
143.	Kim	Sungmi	김성미	GC Biopharma	KOREA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
144.	Kim	Sungryung	김성령	Hana Ventures	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
145.	Kim	Sung-Woo	김성우	Accelvest Inc.	MD	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
146.	Kim	Taeg	김 택수	HotSpot Therapeutics	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
147.	Kim	TaeHyun	김태현	MIT	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
148.	Kim	WonHee	김원희	Spear Bio	MA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
149.	Kim	Yoon Seok	김윤석	Stanford University	CA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
150.	KIM	YOONGI	김윤기	wideNpartners	KOREA	Digital Health / Digital Therapeutics
151.	Kim	Younghoon	김영훈	Tome BioSciences	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
152.	Kim	Yunhye	김윤혜	Boston Children's Hospital	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
153.	KOH	JONG SUNG	고종성	GENOSCO	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
154.	Koh	Kwi Hye	고귀혜	Morphic Therapeutic	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
155.	Kwak	Sang Su	곽상수	Massachusetts General Hospital	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
156.	Kwak	Taekyoung	곽태경	BostonGene	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
157.	Kwak	Yeonui	곽연의	Vertex	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
158.	Kweon	Dae-Hyuk	권대혁	Sungkyunkwan University	KOREA	Infectious Diseases / Vaccines / RNA Therapeutics
159.	Kwon	Kyenghee	권경희	Dongguk University	KOREA	Digital Health / Digital Therapeutics
160.	Kwon	Minji	권민지	KHIDI USA	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
161.	Kwon	Seulki	권슬기	Broad Institute	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
162.	Lee	Agatha	이동은	Batavia Biosciences	CA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
163.	Lee	Anthony	이재용	Seagen	WA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
164.	Lee	Chae Joon	이재준	Ildong Pharmaceutical	KOREA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
165.	Lee	Changsu	이창수	SMsino Technology Investment	KOREA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
166.	Lee	Daeho	이대호	Montefiore Medical Center	NJ	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
167.	Lee	Daeyeon	이대연	University of Pennsylvania	PA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
168.	Lee	Dong Jun	이동준	Adcentrx Therapeutics	CA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
169.	Lee	Dooyoung	이두영	Morphic Therapeutic	MA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
170.	LEE	Eun-Joo	이은주	BIDMC	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases

	Last name	First name	한글	Affiliation	Area	Choose a group
171.	Lee	Grace	이성은	Matica Bio	MA	Cell and Gene Therapy / Rare Diseases
172.	Lee	Hae Ung	이해웅	CytoGen, Inc.	KOREA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
173.	Lee	Hak Seung	이학승	Medical AI	VA	Digital Health / Digital Therapeutics
174.	Lee	Hakho		Harvard Medical School / Massachusetts General Hospital	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
175.	Lee	Heeyong	이희용	G2GBIO	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
176.	Lee	Ho-Young (Grace)	이호영	Elevalue Consulting	CA	CMC / Quality Assurance / Regulatory Affairs / Project Management
177.	Lee	Hungoo	이헌구	MGH/Harvard	MA	Cell and Gene Therapy / Rare Diseases
178.	Lee	Hyun	이현	SM-Sino Technology Investment	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
179.	Lee	Hyun Joon	이현준	Neuronity Therapeutics, Inc.	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
180.	Lee	Hyunjoo	이현주	LG Chem Life Sciences Innovation Center	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
181.	Lee	Hyunsung	이현승	MCPHS	MA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
182.	Lee	Jaekyoo	이재규	GENOSCO	MA	CMC / Quality Assurance / Regulatory Affairs / Project Management
183.	Lee	Jake	이경수	Exorenal Inc	MD	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
184.	Lee	Jeong-Mi	이정미	Brigham and Women's Hospital	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
185.	Lee	Jinhwan	이진환	GNT Pharma	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
186.	Lee	Jinju	이진주	Biotoxtech	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
187.	Lee	Jisun	이지선	UMass Medical School	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
188.	Lee	Jong Heun	이종흔	Txinno Bioscience	KOREA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
189.	Lee	Jong Heun	이종흔	Txinno Bioscience	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
190.	Lee	Joohee	이주희	Fox Rothschild LLP	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
191.	LEE	JOONG HO	이중호	BIO POLICY DIVISON, CHUNGCHEONGBUK-DO	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
192.	Lee	Jooyoung	이주영	Vertex Pharmaceuticals Incorporated	MA	Cell and Gene Therapy / Rare Diseases
193.	LEE	JU-HYUN	이주현	Nathan Kline Institute/NYU Langone Medical Center	NY	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
194.	Lee	Juneyoung	이준영	Moderna	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
195.	LEE	JUNG KUG	이정국	KHIDI USA	MA	Digital Health / Digital Therapeutics
196.	Lee	Kiho	이기호	PhagePro	MA	Infectious Diseases / Vaccines / RNA Therapeutics
197.	Lee	Matt	이승주	Beam Therapeutics	MA	Cell and Gene Therapy / Rare Diseases

	Last name	First name	한글	Affiliation	Area	Choose a group
198.	Lee	Mina		Myriad Life Sciences Co., LTD	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
199.	Lee	Mincheol		Ipon	KOREA	Digital Health / Digital Therapeutics
200.	Lee	Nara	이나라	K-MEDIhub	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
201.	Lee	Sangwon	이상원		MD	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
202.	Lee	Seung Joon	이승준	Biogen	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
203.	Lee	Sujin		MGH	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
204.	Lee	SungJin	이성진	Houston Methodist Hospital	TX	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
205.	Lee	Sunhee	최선희	Regeneron Pharmaceuticals	NY	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
206.	lee	Sunjae	이선재	Chungbuk Provincial Government	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
207.	Lee	Tina	이은별	GSK	DC	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
208.	Lee	Yang	이 양	GSK	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
209.	Lee	Yejin	이예진	Yuhan USA	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
210.	Lee	Yoojin	이유진	CRISPR Therapeutics	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
211.	Lee	Youngmi	이영미	Yuhan Corporation	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
212.	LEE	YUNSUP		LG CHEM LIFE SCIENCES	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
213.	Lim	Hyungwook	임형욱	Novartis Institutes for Biomedical Research	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
214.	Lim	Jin Soo	임진수	Moderna Inc	MA	Cell and Gene Therapy / Rare Diseases
215.	lim	junghee	임정희	intervest	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
216.	lim	sungtaek	임성택	sanofi	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
217.	Min	Dongkook	민동국	MGH Cancer center	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
218.	Min	Kyunghyun	민경현	Kaigene	MD	Immunology-Oncology / Autoimmune / Inflammatory Diseases
219.	Moon	Hyang Mi	문향미	Curevo	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
220.	Moon	Joonsik	문준식	Northeastern University	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
221.	Nam	Hoyun	남호연	VSPharmTech	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
222.	Nam	Joo Hyun	남주현	Massachusettes General Hospital	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
223.	Nam	Woosung		NH Investment & Securities	KOREA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
224.	Noh	Aerin	노애린	Atinum Investment	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations

	Last name	First name	한글	Affiliation	Area	Choose a group
225.	Oh	Sangwook	오상욱	UPENN	PA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
226.	Oh	Se-Yeong	오세영	ProFound Therapeutics	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
227.	Oh	Younghoon	오영훈	Eli Lilly and Company	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
228.	Paark	Soonmahn		KHIDI USA	MA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
229.	Paik	Donggi	백동기	Interon Laboratories	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
230.	Paik	Ik-Hyeon	백익현	WAVE Life Sciences, Inc.	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
231.	Paik	Kate	백은서	University of Pennsylvania	MA	Cell and Gene Therapy / Rare Diseases
232.	Park	Alexander		Tessera Therapeutics	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
233.	Park	Angela	박소영	DongA-ST	MA	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
234.	PARK	CHAN SUN		Txinno Bioscience Inc.	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
235.	PARK	EUNCHAN	박은찬	GNT Pharma, Waksman Inst., Rutgers University	NJ	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
236.	Park	Hong-Jai	박홍재	Yale University	CT	Immunology-Oncology / Autoimmune / Inflammatory Diseases
237.	Park	Hye-Jin	박혜진	CUNY-ASRC	NY	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
238.	Park	Jeonghyuk	박정혁	Prestige Biologics	KOREA	CMC / Quality Assurance / Regulatory Affairs / Project Management
239.	Park	Ji Sun	박지선	TH	NJ	CMC / Quality Assurance / Regulatory Affairs / Project Management
240.	Park	Ji Young	박지영	Merck	NJ	CMC / Quality Assurance / Regulatory Affairs / Project Management
241.	Park	Jihye	박지혜	Dicerna Pharmaceuticals, Inc., a Novo Nordisk company	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
242.	Park	Jihye	박지혜	Broad Institute	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
243.	Park	Jinhwi	박진휘	Yuhan USA	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
244.	Park	Jinseok	박진석	Harvard Medical School	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
245.	Park	Jisoo	박지수	MCPHS University	MA	CMC / Quality Assurance / Regulatory Affairs / Project Management
246.	Park	Jiwhan	박지환	Boston University	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
247.	Park	Jung Young	박정용	Psomagen, Inc.	MD	Infectious Diseases / Vaccines / RNA Therapeutics
248.	Park	Min Young	박민영	New York University	NY	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
249.	Park	Minyoung	박민영	Yuhan Corporation	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
250.	Park	Seung Hun	박승훈	MGH	MA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
251.	Park	ShinYoung	박신영	VSPharmTech	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
252.	Park	Sungjin	박성진	Onegene Biotechnology	KOREA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases

	Last name	First name	한글	Affiliation	Area	Choose a group
253.	Park	Sungyong	박성용	IPON Boston, Inc.	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
254.	Park	SunHee	박선희	Biotoxtech Co., Ltd.	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
255.	Park	Yoojin	박유진	K-MEDIhub	KOREA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
256.	PARK	YOONJEONG	박윤정	UPENN	PA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
257.	Park	Young Bin	박영빈	Calici	TX	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
258.	Park	Youngrong	박영롱	Brigham and Women's Hospital	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
259.	Rim	Nicholas	임내균	Novartis	MA	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
260.	Ro	Sara	노민경	UC Irvine	MD	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
261.	RYU	Eun-Ju	류은주	Dong-A ST USA	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
262.	Ryu	Jaehoon	류재훈	Prestige Biologics	KOREA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
263.	Seo	JeongHwan	서정환	Chungbuk Provincial Government	KOREA	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
264.	Seo	Jeongin	서정인	Brigham and Women's Hospital	MA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
265.	Seo	Stella	서형림	UC San Diego	CA	CMC / Quality Assurance / Regulatory Affairs / Project Management
266.	seol	mina	설민아	Initium therapeutics	MA	Cell and Gene Therapy / Rare Diseases
267.	SHEEN	JOONG HYUK FRANCIS	신중혁	BioNTech US	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
268.	Shim	Jaehoon	심재훈	Boston Children's Hospital	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
269.	Shim	Jaewoo	심재우	INGENIA Therapeutics	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
270.	Shin	Ahyoung	신아영	Illimis Therapeutics	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
271.	Shin	Dongjin	신동진	BL Corp.	KOREA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
272.	Shin	Jaehong	신재홍	Lehigh University	PA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
273.	Shin	Minjae	신민재	Kaigene, Inc.	MD	Immunology-Oncology / Autoimmune / Inflammatory Diseases
274.	SHIN	NARA	신나라	BostonGene	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
275.	Shin	Sook Jung	신숙정	Curachem, Inc.	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
276.	Sim	Sueon	심수언	Biogen	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
277.	SOHN	NICHOLAS NAMSEOK	손남석	N/A	MD	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
278.	Son	Jeongin	손정인	Amgen	CA	CMC / Quality Assurance / Regulatory Affairs / Project Management
279.	Son	Kwangmin	손광민	PhAST Corp.	MA	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development

	Last name	First name	한글	Affiliation	Area	Choose a group
280.	SONG	HOJUHN	송호준	Pinetree Therapeutics, Inc	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
281.	SONG	JI YUN		NA	PA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
282.	Song	Joo Hye	송주혜	Sanofi	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
283.	Song	Saera	송세라	Firstlight Biosciences	NY	Cell and Gene Therapy / Rare Diseases
284.	Song	Byeongmin	송병민	BIO POLICY DIVISON, CHUNGCHEONGBUK-DO	KOREA ,KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations,Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
285.	Suh	Hyunsuk	서현석	Pfizer	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
286.	Suh	Jaehong	서재홍	Massachusetts General Hospital / Harvard Medical School	MA	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging
287.	Suh	Junghae	서정혜	Biogen	MA	Cell and Gene Therapy / Rare Diseases
288.	Suh	Junghee	서정희	Genentech	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
289.	Suh	K. Stephen		DiagnoCine	NJ	CMC / Quality Assurance / Regulatory Affairs / Project Management
290.	Sul	Jae Hoon	설재훈	Merck	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
291.	Sung	Kisa	성기사	Arvinas	CT	Cell and Gene Therapy / Rare Diseases
292.	Sunwoo	Hongjae	선우홍재	Intellia Therapeutics	MA	Cell and Gene Therapy / Rare Diseases
293.	Tak	Youngbin	탁영빈	Yuhan USA	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
294.	Whang	Kenny	황광연	Nexel USA	IL	Metabolic Diseases / Cardiovascular / Diabetes / Respiratory Diseases
295.	Won	Jonghoon	원종훈	Amway	MI	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology
296.	Woo	Jonghye	우종혜	Massachusetts General Hospital and Harvard Medical School	MA	Bioinformatics / A.I. / Machine Learning / Quantitative Science
297.	WOO	Jung Hoon	우정훈	BW Biomed	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
298.	Woo	Yelim	우예림	Boston University	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
299.	Yang	Esther		Retired	TX	Medical Device/In Vitro Diagnostics/Biomedical Engineering/Analytical Method Development
300.	Yim	Ju Yearn	임주연	L & J BIO USA, Inc.	MD	Bioinformatics / A.I. / Machine Learning / Quantitative Science
301.	Yoo	Jinsang	유진상	Accelvest Inc.	MD	Immunology-Oncology / Autoimmune / Inflammatory Diseases
302.	YOO	SEUNGHO	유승호	YOUTH BIO GLOBAL	MD	Cell and Gene Therapy / Rare Diseases
303.	Yoon	Dennis	윤정현	Prestige Biologics	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
304.	Yoon	Donghoon	윤동훈	UAMS	AR	Medicinal Chemistry / Drug Discovery & Delivery / Preclinical / Micro-Nanotechnology

	Last name	First name	한글	Affiliation	Area	Choose a group
305.	Yoon	Hyokyung	윤효경	MCPHS University	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
306.	YOON	INSANG	윤인상	Huons	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
307.	Yoon	Taejin	윤태진	Yuhan Corporation	KOREA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
308.	Yoon	Taewon	윤태원	유한 USA (Boston office)	MA	Business Development/Venture Capital/Entrepreneurship/Legal/Consulting/ Government Relations
309.	You	Jinsam		Ingenia Therapeutics	MA	Immunology-Oncology / Autoimmune / Inflammatory Diseases
310.	Yu	Chongwoo	유종우	US Food and Drug Administration	MD	Clinical Trial & Development / Clinical Pharmacology / Biostatistics
311.	Yun	Hyungjin		Boston University	MA	Digital Health / Digital Therapeutics
312.	Yun	Jay	윤정호	SIMACRO	MA	Digital Health / Digital Therapeutics
313.	Zang	Daniel		Kiyeon Law	DC	Neurological Disorders/Alzheimer's Disease/Parkinson's Disease/Aging

2023 KASBP Spring Symposium Sponsors

YUHAN

KAIST GCC

KMEDI hub
Daegu-Gyeongbuk Medical Innovation Foundation

KHIDI
Korea Health Industry Development Institute

BATAVIA biosciences

GNTPharma 지엔티파마

ILDONG 일동제약

labcorp Drug Development

XtalPi

DONG-A ST

재미한인과학기술자협회 KSEA
Korean-American Scientists and Engineers Association

samyang

ablbio medicine for a better life

Huons

CURACHEM

WOOJUNGBIO

Cyrus Therapeutics

2022-2023 KASBP Sponsors

DAEWOONG

GC Biopharma

SK bioscience

ITP 인천테크노파크 INCHEON TECHNOPARK

연세대학교 YONSEI UNIVERSITY

KAIST

Standigm

NanoEntek

JW 중외제약

MYRIAD LIFE SCIENCES

DONG-A ST

KHIDI USA

KIST Gangneung Institute of Natural Products

재미한인과학기술자협회 KSEA Korean-American Scientists and Engineers Association

KUSCO KOREA - U.S. SCIENCE COOPERATION CENTER

ArentFox Schiff

CURACHEM

Symposium Schedule (U.S. Eastern Daylight Savings Time)

		June 2 (Friday)	June 3 (Saturday)
AM	7		7:00 am – 8:00 am Registration / Breakfast / Opening Remarks
	8		8:00 am – 09:00 am Scientific Session A **Academic Research on Device and Diagnostics**
	9		09:00 am – 10:00 am **Emerging K-Biotech 1 (KAIST-GCC)**
	10		10:00 am – 10:15 am Coffee Break
			10:15 am – 11:00 am **Emerging K-Biotech II (K-MediHub)**
	11		11:00 am – 11:30 am **Sponsor Presentation II**
			11:30 am – 12:00 pm **Fellowship Award**
	12		12:00 pm – 12:15 pm **Group Photo**
PM	1		12:15 pm – 2:00 pm **Lunch/Poster/Networking**
	2	2:00 pm-5:30 pm **Job Fair / Onsite Interview** 4:00 pm – 5:30 pm **YG Program** 4:00 pm – 6:00 pm **Registration and Networking**	2:00 pm – 3:30 pm Scientific Session B **Drug Discovery and Companion Diagnostics**
	3		3:30 pm – 3:45 pm Coffee Break
	4		3:45 pm – 5:00 pm **KHIDI – BD session Panel discussion**
	5		5:00 pm – 5:15 pm Closing Remarks 5:15 pm Networking and Dinner (Registration required)
	6	6:00 pm – 7:30 pm **Opening & Congratulatory Remarks and Dinner** 7:30 pm – 8:45 pm **Keynote Panel Session (Medical device, Diagnostic)** 8:45 pm – 9:40 pm **Sponsor Presentation I** 9:40 pm – 11:30 pm **Networking Session**	06:00 pm – 08:00 am **Sponsor Presentation III** 08:00 pm – **Networking**

We, Chungcheongbuk-do and KAIST GCC are supporting the following companies in Chungcheongbuk-do of Korea to enter the US and Global markets

G2GBIO

PRESTIGE BIOLOGICS

WIREGENE

Biotoxtech

CUePEAK BIO